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lators according to the invention target specific regions in the 
Exon V/Intron V junction of the human HTR2C pre-mRNA 
and drive expression of HTR2C Vb splice isoform, leading 
to increased generation of non-edited strong HTR2C recep-
tor and enhanced serotonin receptor activity. 
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ANTISENSE OLIGONUCLEOTIDE 
MODULATORS OF SEROTONIN RECEPTOR 
2C AND USES THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a national phase entry of international 
application serial number PCT/US2012/064319, filed Nov. 
9, 2012, which claims priority benefit under 35 U.S.C §119 
from U.S. patent application Ser. No. 61/707,592 filed Sep. 
28, 2012 and U.S. patent application Ser. No. 61/558,407 
filed Nov. 10, 2011, all of which are incorporated herein by 
reference. 
BACKGROUND 
Obesity is a serious health crisis with significant associ-
ated morbidity and mortality. It is estimated that about 64% 
of Americans are overweight or obese (roughly about 97 
million adults) with a general belief that the proportion of 
overweight or obese people continues to rise. The preva-
lence of obesity worldwide is also believed to be increasing; 
the World Health Organization projects 700 million adults 
will be clinically obese (BMh:30, body mass index; kg/m2 ) 
by 2015. Co-morbidities include type 2 diabetes, hyperten-
sion, dyslipidemia, heart disease, stroke, arthritis, gallstones, 
liver problems, sleep apnea and even some cancers (e.g., 
endometrial, breast, prostate, and colon cancers). Higher 
body weights are also associated with increases in all-cause 
mortality. 
Numerous treatments for obesity have been developed 
over time, although no treatment has ever gained general 
acceptance. One of these treatments, fenfluramine-phenter-
mine (commonly known as "fen-phen"), which targets 
human serotonin receptor 2C (HTR2C or the 5-HT 2 c recep-
tor) protein, was very effective in achieving weight loss, 
however, it was withdrawn due to side effects such as 
pulmonary hypertension and heart valve damage. Eventu-
ally, it was determined that the side effects offen-phen were 
due to their agonist activity at several serotonin receptors. 
The 5-HT 2 c receptor belongs to the family of seven 
transmembrane domain receptors (7TMRs) that signal to the 
internal cellular environment via heterotrimeric guanine 
nucleotide-binding proteins (G proteins) in response to 
stimulation by hormones, neurotransmitters and pharmaco-
logical ligands. The 5-HT 2 c receptor is found primarily in 
the central nervous system, and particularly in the epithelial 
cells of the choroid plexus. The receptor is implicated in a 
range of other diseases, ranging from obesity-linked condi-
tions such as Prader-Willi Syndrome (PWS) and hyperpha-
gia to psychological disorders to sleep disorders to addic-
tion. 
Existing pharmaceutical HTR2C agonists, such as fen-
phen and locaserin, function through directly targeting the 
HTR2C protein. Such HTR2C agonists would not be effec-
tive in treating diseases like Prader-Willi Syndrome (PWS), 
in which the HTR2C protein is dramatically reduced or even 
absent. 
SUMMARY 
The present invention provides, among other things, oli-
gonucleotide modulators of human 5'-HT2C receptor 
(HTR2C) and improved methods and compositions for 
treating HTR2C-related diseases, disorders or conditions 
based on such modulators. 
2 
As described in the Examples section, the present inven-
tion is, in part, based on the discovery that short antisense 
oligonucleotides that specifically target the Exon V/Intron V 
junction of the human HTR2C pre-mRNA can effectively 
5 drive the expression of the HTR2C Vb isoform by promot-
ing Exon Vb inclusion, which in tum leads to the increased 
level of the strongest serotonin receptor, the non-edited 
receptor. As a result, such short antisense oligonucleotides 
can enhance the serotonin receptor activity in various cells 
10 and tissues including neurons, effecting various anti-obesity 
affects. As shown in the Examples, a short 18 mer antisense 
RNA oligonucleotide is surprisingly effective both in vitro 
and in vivo. It induces the expression of the HTR2C Vb 
15 
isoform in the cell culture at a nanomolar concentration. 
Once injected to the brain, it can be successfully delivered 
to the neurons of hypothalamus and can effectively inhibit or 
reduce food intake in animals. Thus, antisense oligonucle-
otides provided by the present invention can be used to treat 
20 hyperphagia, obesity, and/or Prader Willi Syndrome. 
In one aspect, the present invention provides an antisense 
oligonucleotide of 10-50 nucleotides in length comprising a 
sequence that permits specific hybridization to a target 
region of a human 5'-HT2C receptor (HTR2C) pre-mRNA 
25 under stringent conditions, wherein the target region 
includes a nucleotide sequence 5' UUGGC-
CAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 3' 
(SEQ ID NO:l). In some embodiments, the stringent con-
ditions include 50% formamide with 1 mg heparin at 42° C. 
30 with hybridization carried out overnight and a wash in 
0.2xSSC at 65° C. for 15 minutes. In some embodiments, the 
sequence permits specific hybridization to nucleotides 1-18 
of SEQ ID NO: 1. In some embodiments, the sequence 
permits specific hybridization to nucleotides 10-27 of SEQ 
35 ID NO: 1. In some embodiments, the sequence permits 
specific hybridization to nucleotides 19-36 of SEQ ID NO: 1. 
In some embodiments, the sequence permits specific hybrid-
ization to nucleotides 19-30 of SEQ ID NO: 1. 
In various embodiments, the present invention provides 
40 an antisense oligonucleotide of 10-50 nucleotides in length 
comprising a sequence at least 70% identical to 10 or more 
contiguous nucleotides that appear in 5' AGUAUUGAG-
CAUAGCCGCUGCAAUUCUUAUGGCCAA 3' (SEQ ID 
NO: 15). In some embodiments, the sequence is at least 70% 
45 identical to any of 5' UGCAAUUCUUAUGGCCAA 3' 
(SEQ ID N0:8), 5' CAUAGCCGCUGCAAUUCU 3' (SEQ 
ID N0:4), 5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID 
N0:5), or 5' GAGCAUAGCCGC 3' (SEQ ID N0:7). In 
some embodiments, the sequence is selected from the group 
50 consisting of 5' UGCAAUUCUUAUGGCCAA 3' (SEQ ID 
N0:8), 5' CAUAGCCGCUGCAAUUCU 3' (SEQ ID N04), 
5' AGUAUUGAGCAUAGCCGC 3' (SEQ ID N0:5), or 5' 
GAGCAUAGCCGC 3' (SEQ ID N0:7), and combination 
thereof. In some embodiments, the sequence is 5' 
55 AGUAUUGAGCAUAGCCGC 3' (SEQ ID N0:5). In some 
embodiments, the sequence is 5' GAGCAUAGCCGC 3' 
(SEQ ID N0:7). 
In various embodiments, at least one of the nucleotides in 
the oligonucleotide is a chemically modified oligonucle-
60 otide. For example, in some embodiments, the chemically 
modified oligonucleotide is 2'0 methyl modified. In some 
embodiments, the chemically modified oligonucleotide is 
thiophosphate modified. In some embodiments, the chemi-
cally modified oligonucleotide is modified to be a locked 
65 nucleic acid. 
In another aspect, the present invention provides a phar-
maceutical composition including an antisense oligonucle-
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otide of any of the embodiments described herein and a 
pharmaceutically acceptable carrier. 
In a further aspect, the present invention provides a 
method of modulating human 5'-HT2C receptor (HTR2C) 
activity in a cell including delivering an antisense oligo-
nucleotide of any of the embodiments described herein. In 
some embodiments, the cell is a neuron. In some embodi-
ments, the neuron is in the hypothalamus region of the brain. 
In some embodiments, an antisense oligonucleotide 5' 
AGUAUUGAGCAUAGCCGC 3' (SEQ ID N0:5) is admin- 10 
istered. In some embodiments, the antisense oligonucleotide 
is administered at a concentration of or greater than about 5 
nM (e.g., of or greater than about 10 nM, 15 nM, 20 nM, 25 
nM, 30 nM, 35 nM, 40 nM, 45 nM, or 50 nM). 
In various embodiments, the antisense oligonucleotide is 15 
administered at an amount effective to increase the level of 
the HTR2C Vb isoform as compared to a control level. In 
some embodiments, the antisense oligonucleotide is admin-
istered at an amount effective to increase the level of the 
HTR2C Vb isoform by at least about 20%, 40%, 60%, 80%, 20 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 
4 
lows. It should be understood, however, that the detailed 
description, while indicating embodiments of the present 
invention, is given by way of illustration only, not limitation. 
Various changes and modifications within the scope of the 
invention will become apparent to those skilled in the art 
from the detailed description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The drawings are for illustration purposes only, not for 
limitation. 
FIG. 1 illustrates regulation pathways of the serotonin 2C 
receptor. 
FIG. 2 illustrates exemplary sequence aligmnents of the 
Exon V/Intron V junction region of the 5'-HT2C receptor 
(HTR2C) from various organisms, including human (SEQ 
ID NO: 17), monkey (SEQ ID NO: 18), chimpanzee (SEQ ID 
N0:19), canis (SEQ ID N0:20), sus (SEQ ID N0:21), 
Taurus (SEQ ID N0:22), mouse (SEQ ID N0:23) and rat 
(SEQ ID N0:24). 
FIG. 3 (A) illustrates the structure of an exemplary 
HTR2C minigene containing the alternative Exon Vb 
region. (B) illustrates the sequence of the shaded area within 
the minigene diagram shown in (A), which corresponds to 
the Exon V/Intron V region. The psnoRNA complementary 
or 20 fold as compared to a control level. In some embodi-
ments, a suitable control level is the level of the HTR2C Vb 
isoform in otherwise identical cells but without treatment 
(e.g., the HTR2C Vb isoform level before the treatment). In 
some embodiments, a suitable control level is a level indica-
tive of the HTR2C Vb isoform expression in a patient 
suffering from hyperphagia, obesity, PWS or other HTR2C-
related diseases, disorders or condition. 
25 region is shown as framed sequence. Also depicted are the 
target regions of oligos 1-9. 
FIG. 4 depicts exemplary results from an RNA binding 
assay with oligos 1-9. 
Among other things, the present invention provides vari-
ous methods for treating diseases, disorders or conditions 
associated with HTR2C dysfunction. In some embodiments, 
the present invention provides a method of reducing food 
consumption including administering to a subject in need of 
treatment an antisense oligonucleotide described herein. In 35 
certain embodiments, the administration of an antisense 
oligonucleotide of the invention results in reduction of food 
consumption by at least about 10%, 20%, 30%, 40%, 50%, 
60%, 70%, 80%, 90%, 95%, or more as compared to a 
pre-treatment or no-treatment control. 
FIG. 5 depicts exemplary results showing effects of 
oligonucleotides 1-9 in modulating the expression of 
30 HTR2C Vb vs. Va isoforms. 1 µg of each oligonucleotide 
was added to HEK293 cells transfected with the reporter 
gene shown in FIG. 3. Detection was by RT-PCR. The 
quantification shown in the lower panel is the average of 
three experiments. 
FIG. 6 illustrates exemplary results showing effects of 
certain shortened versions of oligo #5 in modulating the 
expression of HTR2C Vb vs. Va isoforms. 
FIG. 7 illustrates that oligo #5 and psnoRNA HBII-52 
may target the same secondary structure of the Exon 5/Intron 
40 5 region of HTR2C pre-mRNA. Three known splice donor 
sites are shown as X. The psnoRNA complementary region 
is shown as framed sequence. 
In some embodiments, the present invention provides a 
method of treating hyperphagia including administering to a 
subject in need of treatment an antisense oligonucleotide 
described herein. 
In some embodiments, the present invention provides a 
method of treating obesity including administering to a 
subject in need of treatment an antisense oligonucleotide 
described herein. 
In some embodiments, the present invention provides a 
method of treating Prader-Willi syndrome including admin-
istering to a subject in need of treatment an antisense 
oligonucleotide described herein. 
FIG. 8 depicts exemplary dose-response results showing 
effects on HTR2C isoform generation after treating cells 
45 with varying concentrations of oligo #5. 
FIG. 9 depicts exemplary results showing the effects on 
HTR2C isoform generation after treating cells with 3' end or 
5' end Cy3-modified oligo #5. 
FIG. 10 illustrates exemplary results from direct sequenc-
ing of the exon inclusion band generated following treat-
50 ment with oligo #5. 
It will be appreciated the oligonucleotide may be deliv-
ered to the subject by any appropriate method. In some 
embodiments, the antisense oligonucleotide is administered 55 
directly to the brain of the subject. 
FIG. 11 (A) depicts a stereotactical view of a mouse 
cranial injection site. (B) depicts an exemplary fluorescence 
microscopy image of the 3rd ventrical region in a mouse 
brain following injection of Cy3-labeled oligo #5. 
FIG. 12 depicts exemplary results showing the total food 
intake for mice over various time points following injection 
with either oligo #5, control oligo or no treatment (cannu-
lated control). 
In various embodiments, the present invention provides a 
kit including an antisense oligonucleotide of any one of the 
embodiments described herein and tools for administration 
to the brain of a mammal. 
As used in this application, the terms "about" and 
"approximately" are used as equivalents. Any numerals used 
in this application with or without about/approximately are 
meant to cover any normal fluctuations appreciated by one 
of ordinary skill in the relevant art. 
Other features, objects, and advantages of the present 
invention are apparent in the detailed description that fol-
FIG. 13 illustrates exemplary results demonstrating that 
60 oligo #5 reduces food intake in a dose dependent marmer. 
65 
FIG. 14 depicts an exemplary working model for 5'-HT2C 
receptor (HTR2C) Vb isoform signaling. 
DEFINITIONS 
In order for the present invention to be more readily 
understood, certain terms are first defined below. Additional 
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definitions for the following terms and other terms are set 
forth throughout the specification. 
Approximately or about: As used herein, the term 
"approximately" or "about," as applied to one or more 
values of interest, refers to a value that is similar to a stated 
reference value. In certain embodiments, the term "approxi-
mately" or "about" refers to a range of values that fall within 
25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 
11 %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1 %, or less 
in either direction (greater than or less than) of the stated 
reference value unless otherwise stated or otherwise evident 
from the context (except where such number would exceed 
100% of a possible value). 
Amelioration: As used herein, the term "amelioration" is 
meant the prevention, reduction or palliation of a state, or 
improvement of the state of a subject. Amelioration 
includes, but does not require complete recovery or com-
plete prevention of a disease condition. 
Biologically active: As used herein, the phrase "biologi-
cally active" refers to a characteristic of any agent that has 
activity in a biological system, in vitro or in vivo (e.g., in an 
organism). For instance, an agent that, when administered to 
an organism, has a biological effect on that organism, is 
considered to be biologically active. In particular embodi-
ments, where a protein or polypeptide is biologically active, 
a portion of that protein or polypeptide that shares at least 
one biological activity of the protein or polypeptide is 
typically referred to as a "biologically active" portion. 
Dosage form: As used herein, the terms "dosage form" 
and "unit dosage form" refer to a physically discrete unit of 
a therapeutic agent for the patient to be treated. Each unit 
contains a predetermined quantity of active material calcu-
lated to produce the desired therapeutic effect. It will be 
understood, however, that the total dosage of the composi-
tion will be decided by the attending physician within the 
scope of sound medical judgment. 
Improve, increase, or reduce: As used herein, the terms 
"improve," "increase" or "reduce," or grammatical equiva-
lents, indicate values that are relative to a baseline measure-
ment, such as a measurement in the same individual prior to 
initiation of the treatment described herein, or a measure-
ment in a control individual (or multiple control individuals) 
in the absence of the treatment described herein. A "control 
individual" is an individual afilicted with the same form of 
disease as the individual being treated, who is about the 
same age as the individual being treated (to ensure that the 
stages of the disease in the treated individual and the control 
individual(s) are comparable). 
6 
"lumbar area" refers to the area between the third and fourth 
lumbar (lower back) vertebrae and, more inclusively, the 
L2-Sl region of the spine. 
Membrane penetrating peptide: As used herein, the term 
"membrane-penetrating peptide" refers to any peptide that is 
capable of facilitating cellular uptake of a molecule cargo 
(e.g., from nano size particles to small molecules, proteins, 
nucleic acids). A membrane-penetrating peptide can be 
associated with a molecular cargo through chemical linkage, 
10 covalent bonds or non-covalent interactions. Exemplary 
membrane-penetrating peptides include, but are not limited 
to, HIV-TAT, Antp, penetratin, polylysine, polyarginie, 
VP22, Syn Bl, PTD-4, Pep-1, transportan and FGF-4 pep-
tides. Suitable membrane-penetrating peptides can be pro-
15 duced using recombinant and synthetic methods or purified 
from natural sources and encompass both naturally-occur-
ring sequences and modified sequences that retain mem-
brane penetrating ability. In many embodiments, membrane-
penetrating peptides are also capable of penetrating more 
20 then one type of cell membrane. In some embodiments, the 
terms "membrane-penetrating peptides" and "cell penetrat-
ing peptides" are used interchangeably. 
Stability: As used herein, the term "stable" refers to the 
ability of the therapeutic agent to maintain its therapeutic 
25 efficacy (e.g., all or the majority of its intended biological 
activity and/or physiochemical integrity) over extended 
periods of time. The stability of a therapeutic agent, and the 
capability of the pharmaceutical composition to maintain 
stability of such therapeutic agent, may be assessed over 
30 extended periods of time (e.g., for at least 1, 3, 6, 12, 18, 24, 
30, 36 months or more). In general, pharmaceutical com-
positions described herein have been formulated such that 
they are capable of stabilizing, or alternatively slowing or 
preventing the degradation, of one or more therapeutic 
35 agents formulated therewith. In the context of a formulation 
a stable formulation is one in which the therapeutic agent 
therein essentially retains its physical and/or chemical integ-
rity and biological activity upon storage and during pro-
cesses (such as freeze/thaw, mechanical mixing and 
40 lyophilization). For protein stability, it can be measured by 
formation of high molecular weight (HMW) aggregates, loss 
of enzyme activity, generation of peptide fragments and shift 
of charge profiles. For nucleotide stability, it can be mea-
sured by formation of base decomposition products, loss of 
45 binding to a target and generation of fragments. 
Stringent conditions: As used herein, the term "stringent 
conditions" refers to a set of conditions for nucleic acid 
hybridization that allows an oligonucleotide specifically 
binds to a sequence that is complementary to the oligonucle-
50 otide. Typical exemplary stringent conditions include 50% 
formamide with 1 mg heparin at 42° C. with hybridization 
carried out overnight and a wash in 0.2xSSC at 65° C. for 
15 minutes. 
Individual, subject, patient: As used herein, the terms 
"subject," "individual" or "patient" refer to a human or a 
non-human mammalian subject. The individual (also 
referred to as "patient" or "subject'') being treated is an 
individual (fetus, infant, child, adolescent, or adult human) 55 
suffering from a disease. 
Subject: As used herein, the term "subject" means any 
mammal, including humans. In certain embodiments of the 
present invention the subject is an adult, an adolescent or an 
infant. Also contemplated by the present invention are the 
administration of the pharmaceutical compositions and/or 
performance of the methods of treatment in-utero. 
Intrathecal administration: As used herein, the term 
"intrathecal administration" or "intrathecal injection" refers 
to an injection into the spinal canal (intrathecal space 
surrounding the spinal cord). Various techniques may be 60 
used including, without limitation, lateral cerebroventricular 
injection through a burrhole or cistemal or lumbar puncture 
or the like. In some embodiments, "intrathecal administra-
tion" or "intrathecal delivery" according to the present 
invention refers to IT administration or delivery via the 65 
lumbar area or region, i.e., lumbar IT administration or 
delivery. As used herein, the term "lumbar region" or 
Substantial homology: The phrase "substantial homol-
ogy" is used herein to refer to a comparison between amino 
acid or nucleic acid sequences. As will be appreciated by 
those of ordinary skill in the art, two sequences are generally 
considered to be "substantially homologous" if they contain 
homologous residues in corresponding positions. Homolo-
gous residues may be identical residues. Alternatively, 
homologous residues may be non-identical residues will 
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appropriately similar structural and/or functional character-
istics. For example, as is well known by those of ordinary 
skill in the art, certain amino acids are typically classified as 
"hydrophobic" or "hydrophilic" amino acids, and/or as 
having "polar" or "non-polar" side chains Substitution of 
one amino acid for another of the same type may often be 
considered a "homologous" substitution. 
As is well known in this art, amino acid or nucleic acid 
sequences may be compared using any of a variety of 
10 algorithms, including those available in commercial com-
puter programs such as BLASTN for nucleotide sequences 
and BLASTP, gapped BLAST, and PSI-BLAST for amino 
acid sequences. Exemplary such programs are described in 
Altschul, et al., Basic local aligmnent search tool, J. Mal. 
15 
Biol., 215(3): 403-410, 1990; Altschul, et al., Methods in 
Enzymology; Altschul, et al., "Gapped BLAST and PSI-
BLAST: a new generation of protein database search pro-
grams", Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis, 
et al., Bioinformatics: A Practical Guide to the Analysis of 20 
Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), 
Bio informatics Methods and Protocols (Methods in Molecu-
lar Biology, Vol. 132), Humana Press, 1999. In addition to 
identifying homologous sequences, the programs mentioned 
above typically provide an indication of the degree of 25 
homology. In some embodiments, two sequences are con-
sidered to be substantially homologous if at least 50%, 55%, 
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
94%, 95%, 96%, 97%, 98%, 99% or more of their corre-
sponding residues are homologous over a relevant stretch of 30 
residues. In some embodiments, the relevant stretch is a 
complete sequence. In some embodiments, the relevant 
stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 
65, 70, 75,80,85,90,95, 100, 125, 150, 175,200,225,250, 
275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more 35 
residues. 
Substantial identity: The phrase "substantial identity" is 
used herein to refer to a comparison between amino acid or 
nucleic acid sequences. As will be appreciated by those of 
ordinary skill in the art, two sequences are generally con- 40 
sidered to be "substantially identical" if they contain iden-
tical residues in corresponding positions. As is well known 
in this art, amino acid or nucleic acid sequences may be 
compared using any of a variety of algorithms, including 
those available in commercial computer programs such as 45 
BLASTN for nucleotide sequences and BLASTP, gapped 
BLAST, and PSI-BLAST for amino acid sequences. Exem-
plary such programs are described in Altschul, et al., Basic 
local aligmnent search tool, J. Mal. Biol., 215(3): 403-410, 
1990; Altschul, et al., Methods in Enzymology; Altschul et 50 
al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et 
al., Bioinformatics: A Practical Guide to the Analysis of 
Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), 
Bio informatics Methods and Protocols (Methods in Molecu-
lar Biology, Vol. 132), Humana Press, 1999. In addition to 55 
identifying identical sequences, the programs mentioned 
above typically provide an indication of the degree of 
identity. In some embodiments, two sequences are consid-
ered to be substantially identical if at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 60 
95%, 96%, 97%, 98%, 99% A or more of their correspond-
ing residues are identical over a relevant stretch of residues. 
In some embodiments, the relevant stretch is a complete 
sequence. In some embodiments, the relevant stretch is at 
least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 65 
85,90,95, 100, 125, 150, 175,200,225,250,275,300,325, 
350, 375, 400, 425, 450, 475, 500 or more residues. 
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CNS delivery: As used herein, the phrase "CNS delivery" 
or "injection to the brain" typically refers to an administra-
tion method that bypasses the blood brain barrier and 
delivers therapeutic agents directly to the CNS or brain area. 
Target tissues: As used herein, the term "target tissues" 
refers to any tissue that is affected by the defects in or lower 
than desired activity from the 5-HT 2 c receptor, especially 
the central nervous system. In some embodiments, target 
tissues include those tissues in which there is an abnormality 
in the editing of the RNA for the 5-HT 2 c receptor. In some 
embodiments, target tissues include those tissues that dis-
play disease-associated pathology, symptom, or feature. As 
used herein, a target tissue may be a brain target tissue, a 
spinal cord target tissue an/or a peripheral target tissue. 
Exemplary target tissues are described in detail below. 
Therapeutically effective amount: As used herein, the 
term "therapeutically effective amount" refers to an amount 
of a therapeutic agent which confers a therapeutic effect on 
the treated subject, at a reasonable benefit/risk ratio appli-
cable to any medical treatment. The therapeutic effect may 
be objective (i.e., measurable by some test or marker) or 
subjective (i.e., subject gives an indication of or feels an 
effect). In particular, the "therapeutically effective amount" 
refers to an amount of a therapeutic agent or composition 
effective to treat, ameliorate, or prevent a desired disease or 
condition, or to exhibit a detectable therapeutic or preven-
tative effect, such as by ameliorating symptoms associated 
with the disease, preventing or delaying the onset of the 
disease, and/or also lessening the severity or frequency of 
symptoms of the disease. A therapeutically effective amount 
is commonly administered in a dosing regimen that may 
comprise multiple unit doses. For any particular therapeutic 
agent, a therapeutically effective amount (and/or an appro-
priate unit dose within an effective dosing regimen) may 
vary, for example, depending on route of administration, on 
combination with other pharmaceutical agents. Also, the 
specific therapeutically effective amount (and/or unit dose) 
for any particular patient may depend upon a variety of 
factors including the disorder being treated and the severity 
of the disorder; the activity of the specific pharmaceutical 
agent employed; the specific composition employed; the 
age, body weight, general health, sex and diet of the patient; 
the time of administration, route of administration, and/or 
rate of excretion or metabolism of the specific agent 
employed; the duration of the treatment; and like factors as 
is well known in the medical arts. 
Treatment: As used herein, the term "treatment" (also 
"treat" or "treating") refers to any administration of a 
therapeutic agent (e.g., oligonucleotide) that partially or 
completely alleviates, ameliorates, relieves, inhibits, delays 
onset of, reduces severity of and/or reduces incidence of one 
or more symptoms or features of a particular disease, 
disorder, and/ or condition (e.g., hyperphagia, obesity, Prader 
Willi Syndrome). Such treatment may be of a subject who 
does not exhibit signs of the relevant disease, disorder and/or 
condition and/or of a subject who exhibits only early signs 
of the disease, disorder, and/or condition. Alternatively or 
additionally, such treatment may be of a subject who exhib-
its one or more established signs of the relevant disease, 
disorder and/or condition. 
DETAILED DESCRIPTION 
The present invention provides, among other things, 
improved compositions and methods for modulating human 
5'-HT2C receptor (HTR2C) activity and for treatment of a 
disease, disorder or condition associated with HTR2C. In 
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particular, the present invention is based on antisense oli-
gonucleotide modulators of HTR2C that enhance the 
HTR2C activity by promoting Exon Vb inclusion, resulting 
in increased expression of the HTR2C Vb isoform, which in 
turn leads to the increased level of the strong serotonin 
receptor, the non-edited receptor. In some embodiments, the 
present invention provides antisense oligonucleotides that 
specifically target the Exon V/Intron V junction of a human 
5'-HT2C receptor (HTR2C) pre-mRNA. In this application, 
10 
-continued 
GGATCG*GTATGTAGCAATACGTAATCCTATTGAGCATAGCCGTTTCAAT 
TCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCAATTTCTAT 
AG*gtaaataaaactttttggccataagaattgcagcggctatgctcaat 
actttcggattatgtactgtgaacaacgtacagacgtcgactggtaa 
*indicate SA and SB splice donor sites. 
the terms "exon 5", "exon V", "Exon 5" and "Exon V" are 10 Modulators of HTR2C 
used inter-changeably, and the terms "intron 5", "intron V", As discussed in the Examples below, the present inventors 
"Intron 5" and "Intron V" are also used inter-changeably. have successfully identified antisense oligonucleotide 
Various aspects of the invention are described in detail in modulators that change the splicing of the HTR2C. In 
the following sections. The use of sections is not meant to particular, those modulators enhance or promote Exon Vb 
limit the invention. Each section can apply to any aspect of 15 inclusion resulting in increased non-edited version of the 
the invention. In this application, the use of "or" means HTR2C. 
"and/or" unless stated otherwise. 
Human Serotonin Receptor 2C(HTR2C) and Related Dis-
eases and Conditions 
The HTR2C belongs to the family of seven transmem- 20 
brane domain receptors (7TMRs) that signal to the internal 
cellular environment via heterotrimeric guanine nucleotide-
binding proteins (G proteins) in response to stimulation by 
hormones, neurotransmitters and pharmacological ligands. 
The HTR2C significantly regulates mood, anxiety, feeding, 25 
and reproductive behavior. The HTR2C is found primarily in 
the central nervous system, and particularly in the epithelial 
cells of the choroid plexus. The receptor is implicated in a 
range of other diseases, ranging from obesity-linked condi-
tions such as Prader-Willi Syndrome (PWS) and hyperpha- 30 
gia to psychological disorders to sleep disorders to addic-
tion. In particular, it was reported that the 5-HT 2 c receptor 
may underlie the insatiable appetite in Prader-Willi syn-
drome. 
The activity of the HTR2C is partly regulated by RNA 35 
editing. It has been reported that there existed different 
isoforms ofHTR2C with altered G protein-coupling efficacy 
generated by RNA editing, which converts genomically 
encoded adenosine residues into inosines. See, Wang Q., et 
al. "Altered G Protein-Coupling Functions of RNA Editing 40 
Isoform and Splicing Variant Serotonin2 c Receptors," J. 
Neurochem., 74, 1290-1300 (2000), the teachings of which 
are hereby incorporated by reference. 
In particular, two alternative splicing donor sites exist in 
Exon V, which gives rise to Exon Va and Exon Vb. Exon Vb 45 
skipping generates the HTR2C Va splice isoform, which 
results in a truncated and non-functional protein. Exon Vb 
inclusion results in the HTR2C Vb splice isoform, which 
may give rise to edited receptor and non-edited receptor as 
a result of RNA editing mechanism. The edited version 50 
demonstrates weak serotonin response while the non-edited 
version has strong serotonin response. Expression of the 
non-edited receptor prevents the obesity and hyperphagia 
associated with the loss of the HTR2C in transgenic mouse 
model, suggesting that the non-edited receptor is the major 55 
anti-obesity form of the HTR2C. A diagram illustrating 
regulation of the serotonin receptor through alternative 
splicing and RNA editing is shown in FIG. 1. 
An alternative splicing region covering the human 
HTR2C Exon5/Intron5 boundary is shown below (upper- 60 
case: Exon5, lowercase: Intron5). 
(SEQ ID NO, 2) 
ATTATGTCTGGCCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTA 
Antisense Oligonucleotides 
Among other things, the present invention provides anti-
sense oligonucleotides useful for modulation ofHTR2C. An 
antisense oligonucleotide suitable for the present invention 
includes any oligonucleotide that is capable of modulating 
HTR2C or that can rescue or ameliorate one or more 
diseases, disorders or conditions associated with HTR2C. 
In some embodiments, provided antisense oligonucle-
otides are capable of hybridizing or binding to a target 
region ofHTR2C pre-mRNA such that it changes splicing of 
the HTR2C. In some embodiments, provided antisense 
oligonucleotides are capable of hybridizing or binding to a 
target region of HTR2C pre-mRNA such that it enhances or 
promotes Exon Vb inclusion resulting in the HTR2C splice 
isoform Vb. 
It will be appreciated that hybridization of an antisense 
oligonucleotide to a target region of HTR2C pre-mRNA 
may be performed in vitro or in vivo. Hybridization may be 
performed under low, medium, and/or stringent hybridiza-
tion conditions, as is well known in the art. In general, 
stringent hybridization conditions refer to standard hybrid-
ization conditions under which nucleic acid molecules, 
including oligonucleotides, are used to identify molecules 
having complementary nucleic acid sequences. Stringent 
hybridization conditions typically permit binding between 
nucleic acid molecules having at least about 50%, 55%, 
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more 
nucleic acid sequence identity. Standard conditions are dis-
closed, for example, in Sambrook et al., 1989, Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Labs 
Press, the contents of which is incorporated herein by 
reference in its entirety. Formulae to calculate the appropri-
ate hybridization and wash conditions to achieve hybridiza-
tion permitting 50%, 40%, 30%, 20%, 10%, 5% or less 
mismatch of nucleotides are available in the art, for 
example, in Meinkoth et al., 1984, Anal. Biochem. 138, 
267-284; the contents of which is incorporated herein by 
reference in its entirety. It will be appreciated that hybrids 
between oligonucleotides (14-20 bp) and immobilized DNA 
show decreased stability and should be taken into account 
when defining optimal conditions for their hybridization. 
Hybridization condition stringency can be affected by 
buffer ionic strength, base composition of the nucleotide, the 
length of the shortest chain in the duplex (n), and the 
concentration of helix destabilizing agents such as forma-
mide. For example, hybridization stringency can be altered 
by adjusting the salt and/or formamide concentrations and/or 
GATGTTTTATTTTCAACAGCGTCCATCATGCACCTCTGCGCTATATCGCT 
65 by changing the temperature. The stringency can be adjusted 
either during the hybridization step, or in post hybridization 
washes. An example of stringent hybridization conditions 
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In some embodiments, provided oligonucleotides bind to 
a target region that is substantially homologous to SEQ ID 
N0:2. In some embodiments, a suitable HTR2C target 
region includes a nucleotide sequence that has a sequence at 
least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
homologous to SEQ ID N0:2. 
In some embodiments, provided oligonucleotides bind to 
a target region that is substantially identical to SEQ ID 
for hybridization of complementary nucleic acids which 
have more than 100 complementary residues on a filter in a 
Southern or Northern blot is 50% formamide with 1 mg of 
heparin at 42° C., with the hybridization being carried out 
overnight. An example of stringent wash conditions is a 
0.2xSSC wash at 65° C. for 15 minutes. In some embodi-
ments, a high stringency wash is preceded by a low strin-
gency wash to remove back-ground probe signal. An 
example medium stringency wash for a duplex of, e.g., more 
than 100 nucleotides, is lOOxSSC at 45° C. for 15 minutes. 
An example low stringency wash for a duplex of, e.g., more 
than 100 nucleotides, is 4xSSC at 40° C. for 15 minutes. In 
general, a signal to noise ratio of 2x (or higher) than that 
observed for an unrelated probe in the particular hybridiza-
tion assay indicates detection of a specific hybridization. 
10 
N0:2. For example, provided oligonucleotides bind to a 
target region that has a sequence at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID 
N0:2. 
In some embodiments, provided oligonucleotides bind to 
In some embodiments, provided oligonucleotides bind to 
a target region of HTR2C including a nucleotide sequence 
found at the exon5-intron5 boundary. Sequences of the 
human and mouse HTR2C exon5/intron5 sequence are 
shown in Table 1 (uppercase: exon5, lowercase: intron5). 
15 a target region that is substantially homologous to SEQ ID 
N0:3. For example, provided oligonucleotides bind to a 
target region that has a sequence at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 
95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID 
N0:3. 
TABLE 1 
HTR2C Exon5/Intron5 sequence 
human HTR2c ATTATGTCTGGCCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTT SEQ ID 
exon5/intron5TATTTTCAACAGCGTCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAG N0,2 
CAATACGTAATCCTATTGAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGA 
AGATTGCTATTGTTTGGGCAATTTCTATAGgtaaataaaActttttggccataagaa 
Ttgcagcggctatgctcaatactttcggattatgtactgtgaacaacgtacagacgt 
cgactggtaa 
mouse HTR2c ATTATGTCTGGCCTTTACCTAGATATTTGTGCCCCGTCTGGATTTCACTAGATGTGC SEQ ID 
exon5/intron5TATTTTCAACTGCGTCCATCATGCACCTCTGCGCCATATCGCTGGACCGGTATGTAG NQ,3 
CAATACGTAATCCTATTGAGCATAGCCGGTTCAATTCGCGGACTAAGGCCATCATGA 
AGATTGCCATCGTTTGGGCAATATCAATAGgtaattatacctggccatagaatTgca 
Gcggctatgctcaataccttcggattatgtactgtgaacaacctacagacgtcgact 
ggtaa 
In some embodiments, provided oligonucleotides bind to 
a target region that is substantially identical to SEQ ID 
In some embodiments, provided oligonucleotides bind to 
the exon5-intron5 boundary regions shown above (SEQ ID 
N0:2 or SEQ ID N0:3). In some embodiments, provided 
oligonucleotides bind to the intron regions shown in Table 1. 
40 N0:3. For example, provided oligonucleotides bind to a 
target region that has a sequence at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID 
N0:3. 
In some embodiments, provided oligonucleotides bind to a 
target region including a nucleotide sequence 5' UUGGC-
CAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 3' 
(SEQ ID NO:l). In some embodiments, provided oligo- 45 
nucleotides bind to nucleotides 1-18 of SEQ ID NO: 1. In 
some embodiments, provided oligonucleotides bind to 
nucleotides 10-27 of SEQ ID NO: 1. In some embodiments, 
provided oligonucleotides bind to nucleotides 19-36 of SEQ 
ID NO: 1. In some embodiments, provided oligonucleotides 50 
bind to nucleotides 19-30 of SEQ ID NO:l. 
Provided oligonucleotides may bind to a target region of 
a serotonin receptor 2C from a different species. Thus, in 
some embodiments, provided oligonucleotides bind to a 
target region that is substantially homologous to SEQ ID 
NO: 1. For example, provided oligonucleotides may bind to 
a target region that has a sequence at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 
95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID 
NO:l. 
In some embodiments, provided oligonucleotides bind to 
55 
60 
a target region that is substantially identical to SEQ ID 
NO: 1. For example, provided oligonucleotides bind to a 
target region that has a sequence at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 65 
95%, 96%, 97%, 98%, 99% or more identical to SEQ ID 
NO:l. 
In various embodiments, the present invention provides 
an antisense oligonucleotide of 10-50 nucleotides in length 
comprising a sequence at least 70% (e.g., 75%, 80%, 85%, 
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 
more) identical to 10 or more contiguous nucleotides that 
appear in 5' AGUAUUGAGCAUAGCCGCUGCAAUUC-
UUAUGGCCAA 3' (SEQ ID N0:9), which is a comple-
mentary sequence of a target region defined by SEQ ID 
NO:l. 
Exemplary short antisense oligonucleotides suitable for 
the present invention are listed in Table 2: 
TABLE 2 
Short Antisense RNA Oliqonucleotides 
Oligo # 
2 
5 
5-5 
5-3 
5-10 
Sequence ( 5' -3') 
CAUAGCCGCUGCAAUUCU 
AGUAUUGAGCAUAGCCGC 
AGUAUUGAGCAU 
GAGCAUAGCCGC 
GCAUAGCCGC 
UGCAAUUCUUAUGGCCAA 
SEQ ID NO, 
4 
5 
7 
16 
8 
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In some embodiments, an antisense oligonucleotide in 
accordance with the present invention has a sequence that is 
at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
95%, 98%, or 99% identical to any of SEQ ID NO: 4, SEQ 
14 
guanine, thymine, and uridine, which are not as easily 
recognized by endogenous endonucleases. Examples of 
modified bases include uridine and/or cytidine modified at 
the 5-position, e.g., 5-(2-amino )propyl uridine, 5-bromo 
uridine; adenosine and/or guanosines modified at the 8 
position, e.g., 8-bromo guanosine; deaza nucleotides, e.g., 
7-deaza-adenosine; and 0- and N-alkylated nucleotides, 
e.g., N6-methyl adenosine. 
ID N0:5, SEQ ID N0:6, SEQ ID N0:7, SEQ ID NO: 8, and 
SEQ ID N0:16. In some embodiments, the sequence is 
selected from SEQ ID NO: 4, SEQ ID N0:5, SEQ ID N0:6, 
SEQ ID N0:7, SEQ ID NO: 8, SEQ ID N0:16, and 
combinations thereof. In some embodiments, the sequence is 
SEQ ID N0:7. In some embodiments, the sequence is SEQ 
ID N0:5. 
It will be appreciated that an antisense oligonucleotide in 
accordance with the present invention may be of any appro-
priate length. For example, in some embodiments, an anti-
sense oligonucleotide is 10-50 nucleotides in length. In 
some embodiments, an antisense oligonucleotide is 10-30 
nucleotides in length. In certain embodiments, an antisense 
oligonucleotide is 15-40 nucleotides in length. In some 
embodiments, an antisense oligonucleotide is 10, 11, 12, 13, 
14, 15, 16, 17, 1~ 1~ 20,22,2~ 26,28,30,3Z 34,36,38, 
40, 42, 44, 46, 48, or 50 nucleotides in length 
In certain embodiments, the sugar moiety can be modi-
lO fied, typically at the 2'-0H of ribose. Examples of such 
modifications include instances where the 2' OH-group is 
replaced by a group selected from H, OR, R, halo, SH, SR, 
NH2 , NHR, NR2 or ON, where R is C1 -C6 alkyl, alkenyl or 
15 
alkynyl and halo is F, Cl, Br or I. 
Further, chemical modification can encompass modified 
backbones such as morpholino and/or further non-natural 
internucleoside linkages such as siloxane, sulfide, sulfoxide, 
sulfone, sulfonate, sulfonamide, and sulfamate; formacetyl 
20 and thioformacetyl; alkene-containing; methyleneimino and 
methylenehydrazino; amide, and the like. 
"Percent (%) nucleic acid sequence identity" with respect One or more nucleotides (or linkages) within the 
sequences described herein can be modified. For example, a 
20-mer oligonucleotide may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 
25 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 modified 
nucleotides. In certain embodiments, a modified oligonucle-
otide will contain as few modified nucleotides as are nec-
essary to achieve a desired level of in vivo stability and/or 
to the nucleotide sequences identified herein is defined as the 
percentage of nucleotides in a candidate sequence that are 
identical with the nucleotides in the reference sequence, 
after aligning the sequences and introducing gaps, if neces-
sary, to achieve the maximum percent sequence identity. 
Alignment for purposes of determining percent nucleic acid 
sequence identity can be achieved in various ways that are 
within the skill in the art, for instance, using publicly 30 
available computer software such as BLAST, ALIGN or 
Megalign (DNASTAR) software. Those skilled in the art can 
determine appropriate parameters for measuring alignment, 
including any algorithms needed to achieve maximal align-
ment over the full length of the sequences being compared. 35 
Preferably, the WU-BLAST-2 software is used to determine 
amino acid sequence identity (Altschul et al., Methods in 
Enzymology, 266, 460-480 (1996); http://blast.wustl/edu/ 
blast/README.html). WU-BLAST-2 uses several search 
parameters, most of which are set to the default values. The 40 
adjustable parameters are set with the following values: 
overlap span=!, overlap fraction=0.125, world threshold 
(T)=ll. HSP score (S) and HSP S2 parameters are dynamic 
values and are established by the program itself, depending 
upon the composition of the particular sequence, however, 45 
the minimum values may be adjusted and are set as indicated 
above. 
Chemical Modifications 
RNA molecules, including the antisense oligonucleotides 
described herein, may be chemically modified to change 
(e.g., increase or decrease) intracellular stability and half-
life. Possible modifications include the addition of flanking 
sequences at the 5' and/or 3' ends of the molecule or the use 
of phosphorothioate (also known as thiophosphate) linkages 
rather than phosphodiesterase linkages within the backbone 
of the molecule. In addition, one or more ribose groups may 
be modified to add a methyl moiety to the 2'-0H to form a 
2'-methoxy moiety (referred to as 2'0-methyl-modified). 
Also, the 2'-0H moiety can be linked to the or 3' or 4'-carbon 
of ribose by a methylene or ethylene linker, typically a 
methylene linker to the 4'-carbon, to form a "locked nucleic 
acid" (see WO 98/39352 and WO 99/14226, the contents of 
which are incorporated herein by reference). 
In certain embodiments, chemical modification also 
includes the use of nontraditional bases such as inosine, 
queosine, and wybutosine, as well as acetyl-, methyl-, thio-, 
and other similarly modified forms of adenine, cytidine, 
bioaccessibility while maintaining cost effectiveness. 
Therapeutic Uses 
Antisense oligonucleotide modulators of HTR2C 
described herein may be used to treat various HTR2C 
related diseases, disorders and conditions. 
Treatment of Prader-Willi Syndrome 
Prader-Willi Syndrome (PWS) is a genetic disorder, with 
a gene missing on chromosome 15, which is characterized 
by hyperphagia. People with this condition are typically 
obese, have reduced muscle tone and mental ability, and 
have sex glands that produce little or no hormones. 
Newborns with PWS typically have several of the fol-
lowing symptoms: are small for gestational age; have geni-
tals that are not well developed (in boys, the testicles cannot 
be felt in the scrotum); have problems sucking and swal-
lowing, and often do not gain weight; have poor muscle tone 
(hypotonia); often have a weak cry; delayed motor devel-
opment; and show changes in the face, such as "almond-
shaped" eyes and a small, downturned mouth. 
Affected children, beginning at about age 1 to 4, generally 
develop an intense craving for food, leading to weight gain 
50 and morbid obesity. These children also tend to have shorter 
stature and below-normal IQ. In later childhood and in 
adulthood, the symptoms of PWS may include: incomplete 
sexual development (hypogonadism, infertility); low muscle 
mass; short stature; scoliosis; sleep disorders (disruptions of 
55 the normal sleep cycle, sleep apnea); compulsive-like 
behaviors; abnormal glucose tolerance; above normal level 
of the hormone insulin in the blood; failure to respond to 
luteinizing hormone releasing factor; high carbon dioxide 
levels; lack of oxygen supply; right-sided heart failure; and 
60 knee and hip problems. 
Antisense oligonucleotide modulators of HTR2C 
described herein may be used to treat the PWS syndrome. 
The terms, "treat" or "treatment," as used herein, refers to 
amelioration of one or more symptoms associated with the 
65 disease, prevention or delay of the onset of one or more 
symptoms of the disease, and/or lessening of the severity or 
frequency of one or more symptoms of the disease. 
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In some embodiments, treatment refers to partially or 
completely alleviation, amelioration, relief, inhibition, 
delaying onset, reducing severity and/or incidence of one or 
more symptoms in an PWS patient, including, but not 
limited to, hyperphagia, below-normal IQ, low muscle mass; 
short stature; scoliosis; sleep disorders (disruptions of the 
normal sleep cycle, sleep apnea); compulsive-like behav-
iors; abnormal glucose tolerance; above normal level of the 
hormone insulin in the blood; failure to respond to luteiniz-
ing hormone releasing factor; high carbon dioxide levels; 10 
lack of oxygen supply; right-sided heart failure; and knee 
and hip problems. 
In some embodiments, treatment refers to reduced food 
intake or consumption in a subject in need of treatment. In 
certain embodiments, the amount of food intake or con- 15 
sumption may be reduced by at least about 10%, 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 90%, 95%, or more as com-
pared to a pre-treatment or no-treatment control (e.g., the 
amount of food intake or consumption by the same subject 
pre-treatment or the amount of food intake or consumption 20 
by a control subject with similar diseased or developmental 
stage but without treatment). 
In some embodiments, treatment refers to improved body 
weight loss (e.g., total weight loss, percent body weight loss 
per week, per month, per two months, per six months, etc.). 25 
In certain embodiments, total body weight loss is, on aver-
age, about 0.1 kg, about 0.2 kg, about 0.3 kg, about 0.4 kg, 
about 0.5 kg, about 0.6 kg, about 0.7 kg, about 0.8 kg, about 
0.9 kg, about 1 kg, about 1.1 kg, about 1.2 kg, about 1.3 kg, 
about 1.4 kg, about 1.5 kg, about 1.6 kg, about 1.7 kg, about 30 
1.8 kg, about 1.9 kg, about 2 kg, about 2.1 kg, about 2.2 kg, 
about 2.3 kg, about 2.4 kg, about 2.5 kg, about 2.6 kg, about 
2.7 kg, about 2.8 kg, about 2.9 kg, about 3 kg, or more, per 
week. In some embodiments, percent body weight loss is a 
decrease by, on average, about 5%, about 10%, about 15%, 35 
about 20%, about 25%, about 30%, about 35%, about 40%, 
about 45%, about 50%, about 55%, about 60%, about 65%, 
about 70%, about 75%, about 80%, about 85%, about 90%, 
about 95%, about 100%, or more per week. As used herein, 
percent body weight loss is determined by comparing the 40 
total body weight loss to the base total body weight before 
the loss. 
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about 55%, about 60%, about 65%, about 70%, about 75%, 
about 80%, about 85%, about 90%, about 95%, about 100%, 
about 105%, about 110%, about 115%, about 120%, about 
125%, about 130%, about 135%, about 140%, about 145%, 
about 150%, about 155%, about 160%, about 165%, about 
170%, about 175%, about 180%, about 185%, about 190%, 
about 195%, about 200% or more, as compared to the 
average life expectancy of one or more control individuals 
with Prader-Willi Syndrome without treatment. In some 
embodiments, treatment according to the present invention 
results in an increased life expectancy of a patient by more 
than about 1 month, about 2 months, about 3 months, about 
4 months, about 5 months, about 6 months, about 7 months, 
about 8 months, about 9 months, about 10 months, about 11 
months, about 12 months, about 2 years, about 3 years, about 
4 years, about 5 years, about 6 years, about 7 years, about 8 
years, about 9 years, about 10 years or more, as compared 
to the average life expectancy of one or more control 
individuals with similar disease form without treatment. In 
some embodiments, treatment according to the present 
invention results in long term survival of a patient. As used 
herein, the term "long term survival" refers to a survival 
time or an increased life expectancy of longer than about 10 
years, 15 years, 20 years, 25 years, 30 years or longer. 
Treatment of other HTR2C-Associated Diseases 
Inventive methods and compositions of the present inven-
tion are particularly useful for treating those diseases having 
a 5'-HT2C receptor (HTR2C) etiology, component or rela-
tionship. Giuseppe's 5-HT2C Receptors in the Pathophysi-
ology of CNS Disease, 1st Edition, G. Di Giovanni et. al. 
(Humana Press, 2010; incorporated herein by reference) 
discloses various diseases associated, caused and/or affected 
by HTR2C dysregulation. Representative diseases having an 
HTR2C etiology or component include, for example and 
without limitation, metabolic disorders such as obesity, 
hyperphagia, lack of satiety, and diabetes; psychiatric dis-
orders such as schizophrenia (Sodhi, M, S. et. al., RNA 
editing of the 5-HT(2C) receptor is reduced in schizophre-
nia, Molecular Psychiatry, 2001; (6): 373-9; incorporated 
herein by reference), depression (Iwamoto, K, et. al., Esti-
mating RNA editing efficiency of five editing sites in the 
serotonin 2C receptor by pyrosequencing, RNA, 2005; (11 ): 
1596-1603; incorporated herein by reference), suicidal ten-
In some embodiments, treatment refers to reduced or 
prevented weight gain (e.g., total weight gain, percent body 
weight gain per week, per month, per two months, per six 
months, etc.). In some embodiments, total body weight gain 
is, on average, less than about 0.1 kg, about 0.2 kg, about 0.3 
kg, about 0.4 kg, about 0.5 kg, about 0.6 kg, about 0.7 kg, 
about 0.8 kg, about 0.9 kg, about 1 kg, about 1.1 kg, about 
45 dencies (Niswender, C, M., et. al., RNA editing of the human 
serotonin 5-HT2C receptor: alterations in suicide and impli-
cations for erotonergic pharmacotherapy, Neuropsychop-
harmacology, 2001; (24 ): 4 78-91, incorporated herein by 
reference) and bipolar disorder; epilepsy including sensitiv-
50 ity to seizure and a reduced seizure threshold; addictive 
disorders (e.g., cocaine addiction, tetrahydrocannabinol 
addiction, nicotine addition); and sleep disorders (insomnia, 
abnormal REM sleep). Several of the listed methods involve 
delivery of one of the compositions described herein to 
1.2 kg, about 1.3 kg, about 1.4 kg, about 1.5 kg, about 1.6 
kg, about 1.7 kg, about 1.8 kg, about 1.9 kg, about 2 kg, 
about 2.1 kg, about 2.2 kg, about 2.3 kg, about 2.4 kg, about 
2.5 kg, about 2.6 kg, about 2.7 kg, about 2.8 kg, about 2.9 
kg, or about 3 kg, per week. In some embodiments, percent 
body gain is, on average, less than about 0.1 %, about 0.5%, 
about 1 %, about 1.5%, about 2%, about 2.5%, about 3%, 
about 3.5%, about 4%, about 5%, about 10%, about 15%, 
about 20%, or about 25%, per week. As used herein, percent 
body weight gain is determined by comparing the total body 
weight gain to the base total body weight before the gain. 60 
55 neurons, such as those located in the brain. 
In other embodiments, treatment refers to increased sur-
vival (e.g., survival time). For example, treatment can result 
in an increased life expectancy of a patient. In some embodi-
ments, treatment according to the present invention results 
in an increased life expectancy of a patient by more than 65 
about 5%, about 10%, about 15%, about 20%, about 25%, 
about 30%, about 35%, about 40%, about 45%, about 50%, 
Metabolic Disorders 
A first group of conditions treated according to the present 
invention are metabolic disorders. Such metabolic disorders 
can be caused by insufficient metabolism of calorie intake 
(e.g., obesity), elevated blood glucose (e.g., diabetes) or an 
inability to control appetite (e.g., hyperphagia). 
Obese individuals or individuals suffering from obesity 
are generally individuals having a body mass index (BMI) of 
at least 25 or greater or at least 30 or greater. Obesity may 
or may not be associated with insulin resistance. Obesity can 
lead to other conditions such as type 2 diabetes, hyperten-
sion, dyslipidemia, heart disease, stroke, arthritis, gallstones, 
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liver problems, sleep apnea and some cancers (e.g., endo-
metrial, breast, prostate, and colon cancers). 
Diabetes refers to high blood sugar or ketoacidosis, as 
well as chronic, general metabolic abnormalities arising 
from a prolonged high blood sugar status or a decrease in 
glucose tolerance. Diabetes encompasses both the type I and 
type II (Non Insulin Dependent Diabetes Mellitus or 
NIDDM) forms of the disease. Subjects with type II diabetes 
often suffer from insulin resistance, which refers to a state in 
which a normal amount of insulin produces a subnormal 10 
biologic response relative to the biological response in a 
subject that does not have insulin resistance. An insulin 
resistance disorder generally refers to any disease or condi-
tion that is caused by or contributed to by insulin resistance. 
Hyperphagia, also known as polyphagia, refers to exces- 15 
sive hunger and/or an excessive impulse to eat. 
Psychiatric Disorders 
Psychiatric disorders that can be treated using the com-
positions and methods described herein include, but are not 
limited to, psychosis, schizophrenia, anxiety (Hackler, E, A., 20 
et. al., 5-HT(2C) receptor RNA editing in the amygdala of 
C57BL/6J, DBA/2J, and BALB/cJ mice, Neurosci Res, 2006; 
(55): 96-104; incorporated herein by reference) (including 
generalized anxiety disorder, panic disorder, social phobia, 
obsessive compulsive disorder, and post-traumatic stress 25 
disorder (PTSD)), suicidal tendencies and mood disorders 
(including depression, mania, bipolar disorders). In certain 
embodiments, one or more of schizophrenia, depression, 
suicidal tendencies and bipolar disorder are treated. 
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dependency, despite the harmful consequences on the health, 
family, professional life, etc. of which the dependent person 
is fully aware. Examples of addictions treatable by the 
methods described herein include cocaine addiction, tetra-
hydrocannabinol addiction, opioid addiction and nicotine 
addition. Treatment can be assessed, for example, by reduc-
tion in cravings, reduction in use of a substance, reduction 
of relapse of addiction. 
Sleep Disorders 
The present invention also provides compos1t10ns and 
methods that treat sleep disorders. Sleep disorders include 
an inability to fall asleep or stay asleep, collectively known 
as insomnia. Insomnia can be transient or chronic. Sleep 
disorders also include conditions where the quality of sleep 
is disturbed, such as when a subject has abnormal REM 
sleep. 
Autonomic Dysregulation 
The present invention also provides compos1t10ns and 
methods that treat disease associated with dysregulation of 
one or more physiological functions controlled by the auto-
nomic nervous system. Autonomic dysregulation (Dysauto-
nomia) includes an inability to maintain homeostasis and 
regulate a response to basic changes such as temperature, 
walking, sitting, sleeping, eating, desiring, digesting food or 
thirst. Autonomic dysregulation also includes conditions 
related to thermal regulation, in which the subject resides is 
a state of hypo- and/or hyperthermia. Data suggests that 
modulation of HTR2C, such as with a HTR2C agonist, can 
Epilepsy 30 play an important role in controlling thermal regulation 
(Deecher, Darlene, C., et. al., Alleviation of Thermoregula-
tory Dysfunction with the New Serotonin and Norepineph-
rine Reuptake Inhibitor Desvenlafaxine Succinate in Ova-
Epilepsy and associated conditions represent another 
group of disorders that can be treated using the compositions 
and methods described herein. Epilepsy is a common 
chronic neurological disorder that is characterized by recur-
rent unprovoked seizures. These seizures may be transient 35 
signs and/or symptoms due to abnormal, excessive or syn-
chronous neuronal activity in the brain. Illustrative examples 
of epileptic seizures treatable with the methods and compo-
sitions described herein include tonic-clonic, clonic (with or 
without tonic features), absence (typical or atypical), myo- 40 
clonic absence, tonic, myoclonic, massive bilateral myoclo-
nus, negative myoclonus, eyelid myclonia (accompanied or 
not by absence seizures), myoclonic-atonic, atonic, reflex, 
focal sensory (with elementary sensory symptoms, such as 
occipital and parietal lobe seizures, or experiential sensory 45 
symptoms, such as temporo parieto occipital junction sei-
zures, and the like), focal motor (with elementary clonic 
motor signs, with asymmetrical tonic motor signs or seizure, 
such as supplementary motor seizures, with typical automa-
tisms, also referred to as temporal lobe automatisms, such as 50 
mesial temporal lobe seizures, with hyperkinetic automa-
tisms, with focal negative myoclonus, and the like), inhibi-
tory motor, gelastic, hemiclonic, secondarily generalized, 
reflex seizures in focal epilepsy syndromes, generalized 
tonic-clonic status epilepticus, clonic status epilepticus, 55 
absence status epilepticus, tonic status epilepticus, myoclo-
nic status epilepticus, epilepsia partialis continua, aura con-
tinua, limbic status epilepticus, hemiconvulsive status epi-
lepticus. Methods of the invention include reducing the 
likelihood of epilepsy and reducing the severity of a seizure. 60 
Addictive Disorders 
riectomized Rodent Models, Neuroendocrinology, 2007; (3): 
1376; and Findlay, J. D., et. al, The mechanism of body 
temperature changes induced by intraventicular injections 
of adrenaline, noradrenaline and 5-hydroxytryptamine in 
the ox (bas Taurus), The journal of Physiology, 1967; (189): 
329-336; both of which are incorporated herein by refer-
ence.) 
Pharmaceutical Compositions 
The present invention further provides pharmaceutical 
compositions comprising therapeutic actives in accordance 
with the invention (e.g., antisense oligonucleotides), 
together with one or more pharmaceutically acceptable 
excipients. Such pharmaceutical compositions may option-
ally comprise one or more additional therapeutically-active 
substances. 
Although the descriptions of pharmaceutical composi-
tions provided herein are principally directed to pharmaceu-
tical compositions which are suitable for ethical adminis-
tration to humans, it will be understood by the skilled artisan 
that such compositions are generally suitable for adminis-
tration to animals of all sorts. Modification of pharmaceu-
tical compositions suitable for administration to humans in 
order to render the compositions suitable for administration 
to various animals is well understood, and the ordinarily 
skilled veterinary pharmacologist can design and/or perform 
such modification with merely ordinary, if any, experimen-
tation. 
Another group of disorders that can be treated using the 
compositions and methods described herein are addictive 
disorders, particularly those disorders where serotonin plays 
a role in maintaining the addictive behavior. Typically, 
addiction is classified as a behavioral disorder, characterized 
by a compulsive search for the product that causes this 
Formulations of the pharmaceutical compos1t10ns 
described herein may be prepared by any method known or 
hereafter developed in the art of pharmacology. In general, 
65 such preparatory methods include the step of bringing the 
active ingredient into association with a diluent or another 
excipient and/or one or more other accessory ingredients, 
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and then, if necessary and/or desirable, shaping and/or 
packaging the product into a desired single- or multi-dose 
unit. 
A pharmaceutical composition in accordance with the 
invention may be prepared, packaged, and/or sold in bulk, as 
a single unit dose, and/or as a plurality of single unit doses. 
As used herein, a "unit dose" is discrete amount of the 
pharmaceutical composition comprising a predetermined 
amount of the active ingredient. The amount of the active 
ingredient is generally equal to the dosage of the active 
ingredient which would be administered to a subject and/or 
a convenient fraction of such a dosage such as, for example, 
one-half or one-third of such a dosage. 
20 
In some embodiments, liposomes may be used to deliver 
antisense oligonucleotides described herein. As used herein, 
a liposome is an artificially-prepared vesicle composed of a 
lipid bilayer. Liposomes can be prepared by disrupting 
biological membranes (such as by sonication). Liposomes 
may include natural phospholipids, or mixed lipid chains 
with surfactant properties (e.g., egg phosphatidyletha-
nolamine) A liposome design may employ surface ligands 
for targeting desired target tissues. 
10 Administration 
The present invention provides methods of administering 
an effective amount of a therapeutic active described herein 
(e.g., an antisense oligonucleotide) to a subject in need of 
treatment. 
Antisense oligonucleotides described herein may be 
administered through various administration routes includ-
ing, but not limited to, intravenous, subcutaneous, intramus-
cular, parenteral, transdermal, or transmucosal (e.g., oral or 
nasal). In some embodiments, antisense oligonucleotides 
Relative amounts of the active ingredient, the pharma-
15 
ceutically acceptable excipient, and/or any additional ingre-
dients in a pharmaceutical composition in accordance with 
the invention will vary, depending upon the identity, size, 
and/or condition of the subject treated and further depending 
upon the route by which the composition is to be adminis-
tered. By way of example, the composition may comprise 
between 0.1 % and 100% (w/w) active ingredient. 
20 described herein are directly delivered to the central nervous 
system (i.e., brain) of a subject in need of treatment. 
CNS Delivery 
Pharmaceutical formulations may additionally comprise a 
pharmaceutically acceptable excipient, which, as used 
herein, includes any and all solvents, dispersion media, 
diluents, or other liquid vehicles, dispersion or suspension 
aids, surface active agents, isotonic agents, thickening or 
emulsifying agents, preservatives, solid binders, lubricants 
and the like, as suited to the particular dosage form desired. 
Remington's The Science and Practice of Pharmacy, 21st. 
Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, 
Baltimore, Md., 2006; incorporated herein by reference) 
discloses various excipients used in formulating pharmaceu-
tical compositions and known techniques for the preparation 
thereof. Except insofar as any conventional excipient 
medium is incompatible with a substance or its derivatives, 
such as by producing any undesirable biological effect or 
otherwise interacting in a deleterious manner with any other 
component(s) of the pharmaceutical composition, its use is 
contemplated to be within the scope of this invention. 
In some embodiments, a pharmaceutically acceptable 
excipient is at least 95%, at least 96%, at least 97%, at least 
98%, at least 99%, or 100% pure. In some embodiments, an 
excipient is approved for use in humans and for veterinary 
use. In some embodiments, an excipient is approved by 
United States Food and Drug Administration. In some 
embodiments, an excipient is pharmaceutical grade. In some 
embodiments, an excipient meets the standards of the United 
States Pharmacopoeia (USP), the European Pharmacopoeia 
(EP), the British Pharmacopoeia, and/or the International 
Pharmacopoeia. 
Pharmaceutically acceptable excipients used in the manu-
facture of pharmaceutical compositions include, but are not 
limited to, inert diluents, dispersing and/or granulating 
agents, surface active agents and/or emulsifiers, disintegrat-
ing agents, binding agents, preservatives, buffering agents, 
lubricating agents, and/or oils. Such excipients may option-
ally be included in pharmaceutical formulations. Excipients 
such as cocoa butter and suppository waxes, coloring agents, 
coating agents, sweetening, flavoring, and/or perfuming 
agents can be present in the composition, according to the 
judgment of the formulator. 
General considerations in the formulation and/or manu-
facture of pharmaceutical agents may be found, for example, 
in Remington: The Science and Practice of Pharmacy 21st 
ed., Lippincott Williams & Wilkins, 2005 (incorporated 
herein by reference). 
Typically, direct CNS delivery or injection to the brain 
bypasses the blood brain barrier and delivers therapeutic 
25 agents directly to the brain tissues. Suitable CNS delivery 
techniques and routes include, but are not limited to, intra-
parenchymal, intracerebral, intravetricular cerebral (ICY), 
intrathecal (e.g., IT-Lumbar, IT-cisterna magna) administra-
tions and any other techniques and routes for injection 
30 directly or indirectly to the CNS and/or CSF. 
In some embodiments, intrathecal delivery may be used 
according to the present invention. As used herein, intrath-
ecal administration (also referred to as intrathecal injection) 
refers to an injection into the spinal canal (intrathecal space 
35 surrounding the spinal cord). Various techniques may be 
used including, without limitation, lateral cerebroventricular 
injection through a burrhole or cisternal or lumbar puncture 
or the like. Exemplary methods are described in Lazorthes 
et al. Advances in Drug Delivery Systems and Applications 
40 in Neurosurgery, 143-192 and Omaya et al., Cancer Drug 
Delivery, 1: 169-179, the contents of which are incorporated 
herein by reference. 
Typically, a therapeutic composition may be injected at 
any region surrounding the spinal canal. In some embodi-
45 ments, a therapeutic composition is injected into the lumbar 
area or the cisterna magna or intraventricularly into a 
cerebral ventricle space. As used herein, the term "lumbar 
region" or "lumbar area" refers to the area between the third 
and fourth lumbar (lower back) vertebrae and, more inclu-
50 sively, the L2-Sl region of the spine. Typically, intrathecal 
injection via the lumbar region or lumber area is also 
referred to as "lumbar IT delivery" or "lumbar IT adminis-
tration." The term "cisterna magna" refers to the space 
around and below the cerebellum via the opening between 
55 the skull and the top of the spine. Typically, intrathecal 
injection via cisterna magna is also referred to as "cisterna 
magna delivery." The term "cerebral ventricle" refers to the 
cavities in the brain that are continuous with the central 
canal of the spinal cord. Typically, injections via the cerebral 
60 ventricle cavities are referred to as intravetricular Cerebral 
(ICY) delivery. 
In some embodiments, intrathecal administration may be 
performed by either lumbar puncture (i.e., slow bolus) or via 
a port-catheter delivery system (i.e., infusion or bolus). In 
65 some embodiments, the catheter is inserted between the 
laminae of the lumbar vertebrae and the tip is threaded up 
the thecal space to the desired level. 
US 9,567,585 B2 
21 
Blood Brain Barrier-Crossing Moieties 
22 
positions of the present invention. A therapeutically effective 
amount is commonly administered in a dosing regimen that 
may comprise multiple unit doses. For any particular com-
position, a therapeutically effective amount (and/or an 
appropriate unit dose within an effective dosing regimen) 
may vary, for example, depending on the desired therapeutic 
effects, route of administration or on combination with other 
pharmaceutical agents. Also, the specific therapeutically 
effective amount (and/or unit dose) for any particular patient 
In some embodiments, antisense RNA oligonucleotides 
described herein may be modified to facilitate crossing the 
blood brain barrier (BBB) and/or cellular uptake into neu-
rons. For example, antisense RNA oligonucleotides 
described herein may be associated with a BBB-crossing 
moiety. In some embodiments, a suitable BBB-crossing 
moiety binds to a receptor on the surface of brain cells, 
thereby inducing, e.g., receptor-mediated endocytosis. 
Exemplary BBB-crossing moieties include, but are not 
limited to, hormones (e.g., thyroids, steroids) and peptides 
(e.g., IGF-I, IGF-II, insulin, or transferrin). In some embodi-
ments, antisense RNA oligonucleotides described herein are 
associated with a cell- or membrane-penetrating peptide to 
facilitate uptake into brain cells, such as neurons. Without 
wishing to be bound by theory, it is contemplated that cell-
or membrane-penetrating peptides are particularly useful in 
facilitating cellular uptake of antisense RNA oligonucle-
otides into arcuate nucleus neurons, for example, proopi-
omelanocortin (POMC) positive neurons of the hypothala-
mus, which display a leaky BBB. 
10 may depend upon a variety of factors including the disorder 
being treated and the severity of the disorder; the activity of 
the specific pharmaceutical agent employed; the specific 
composition employed; the age, body weight, general 
health, sex and diet of the patient; the time of administration, 
15 route of administration; the duration of the treatment; and 
like factors as is well known in the medical arts. 
In some embodiments, a therapeutically effective dose 
may range from about 0.005 mg/kg weight to 500 mg/kg 
weight, e.g., from about 0.005 mg/kg weight to 400 mg/kg 
Exemplary cell- or membrane-penetrating peptides 
include, but are not limited to, HIV-TAT, Antp, penetratin, 
polylysine, polyarginie, VP22, Syn Bl, PTD-4, Pep-1, trans-
portan and FGF-4 peptides. See e.g., Langel, U. (ed.), 
"Cell-Penetrating Peptides: Processes and Applications", 
CRC Press, Boca Raton, Fla., 2002; Arzumanov, Abes, R., 
20 weight, from about 0.005 mg/kg weight to 300 mg/kg 
weight, from about 0.005 mg/kg weight to 200 mg/kg 
weight, from about 0.005 mg/kg weight to 100 mg/kg 
weight, from about 0.005 mg/kg weight to 90 mg/kg weight, 
from about 0.005 mg/kg weight to 80 mg/kg weight, from 
et. al., Arginine-rich cell penetrating peptides: Design, 
structure-activity, and applications to alter pre-mRNA splic-
ing by steric-block oligonucleotides, 2008, J Pept Sci; (14): 
455-60; Said, Hassane, F., Cell penetrating peptides: over-
view and applications to the delivery of oligonucleotides, 
2010, Cell Mo! Life Sci; (67):715-26 for further discussion 
and all of which are incorporated herein by reference. 
Suitable cell- or membrane-penetrating peptides encompass 
both naturally-occurring peptides and modified peptides that 
retain membrane penetrating ability and can be produced 
using recombinant and synthetic methods or purified from 
natural sources. 
25 about 0.005 mg/kg weight to 70 mg/kg weight, from about 
0.005 mg/kg weight to 60 mg/kg weight, from about 0.005 
mg/kg weight to 50 mg/kg weight, from about 0.005 mg/kg 
weight to 40 mg/kg weight, from about 0.005 mg/kg weight 
to 30 mg/kg weight, from about 0.005 mg/kg weight to 25 
30 mg/kg weight, from about 0.005 mg/kg weight to 20 mg/kg 
weight, from about 0.005 mg/kg weight to 15 mg/kg weight, 
from about 0.005 mg/kg weight to 10 mg/kg weight. 
In some embodiments, the therapeutically effective dose 
may also be defined by mg/kg brain weight. As one skilled 
A BBB-crossing moiety including a cell- or membrane-
penetrating peptide may be attached at the 5' end or 3' end 
35 in the art would appreciate, the brain weights and body 
weights can be correlated. Dekaban AS. "Changes in brain 
weights during the span of human life: relation of brain 
weights to body heights and body weights," Ann Neural 
1978; 4:345-56. Thus, in some embodiments, the dosages 
40 can be converted as shown in Table 3. 
of the oligo. It will be appreciated that a BBB-crossing 
moiety including a cell- or membrane-penetrating peptide 
may be associated with an antisense RNA oligo in any 
manner. For example, a BBB-crossing moiety (e.g., a cell- 45 
or membrane-penetrating peptide) may be chemically con-
jugated, or fused to an antisense RNA oligo directly or 
indirectly via a peptide linker or spacer. In some embodi-
ments, a BBB-crossing moiety (e.g., a cell- or membrane-
penetrating peptide) may be associated with an antisense 50 
RNA oligo via non-covalent interactions. 
Inventive methods of the present invention contemplate 
single as well as multiple administrations of a therapeuti-
cally effective amount of antisense oligonucleotides 
described herein. Antisense oligonucleotides can be admin- 55 
istered at regular intervals, depending on the nature, severity 
and extent of the subject's condition. In some embodiments, 
a therapeutically effective amount of an antisense oligo-
nucleotide of the present invention may be administered 
periodically at regular intervals (e.g., once every year, once 60 
every six months, once every five months, once every three 
months, bimonthly (once every two months), monthly (once 
every month), biweekly (once every two weeks), weekly, 
twice a week, three times a week, daily, or twice a day). 
As described above, the term "therapeutically effective 65 
amount" is largely determined based on the total amount of 
the therapeutic agent contained in the pharmaceutical com-
TABLE 3 
Dosage conversion 
Correlation between Brain Weights, body weights and ages of males 
Age (year) 
3 (31-43 months) 
4-5 
Brain weight (kg) 
1.27 
1.30 
Body weight (kg) 
15.55 
19.46 
In some embodiments, the therapeutically effective dose 
may also be defined by mg/15 cc of cerebrospinal fluid 
(CSF). As one skilled in the art would appreciate, therapeu-
tically effective doses based on brain weights and body 
weights can be converted to mg/15 cc ofCSF. For example, 
the volume of CSF in adult humans is approximately 150 
mL (Johanson CE, et al. "Multiplicity of cerebrospinal fluid 
functions: New challenges in health and disease," Cerebro-
spinal Fluid Res. 2008 May 14; 5:10). Therefore, single dose 
injections of 0.1 mg to 50 mg protein to adults would be 
approximately 0.01 mg/15 cc ofCSF (0.1 mg) to 5.0 mg/15 
cc of CSF (50 mg) doses in adults. 
It is to be further understood that for any particular 
subject, specific dosage regimens should be adjusted over 
time according to the individual in need and the professional 
judgment of the person administering or supervising the 
administration of the therapeutic agent and that dosage 
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ranges set forth herein are exemplary only and are not 
intended to limit the scope or practice of the claimed 
invention. 
Gene Therapy 
In some embodiments, antisense oligonucleotides may be 
delivered as naked recombinant RNAs in pharmaceutical 
compositions through conventional administration routes 
described above. In some embodiments, constructs encoding 
an antisense oligonucleotide of interest may be delivered 
through gene therapy approaches. Various gene therapy 
vectors may be used to practice the present invention. 
10 
24 
Various methods may be used to deliver viral vectors 
encoding a gene of interest and are known in the art. For 
example, recombinant adeno- or adeno-associated virus 
based vectors may be delivered through trachea instillation 
(Rosenfeld et al., 1991; Rosenfeld et al., 1992), muscle 
injection (Ragot et al., 1993), peripheral intravenous injec-
tions (Herz and Gerard, 1993), stereotactic inoculation into 
the brain (Le Gal La Salle et al., 1993), and intrathecal 
delivery as described herein. 
Kits 
The present invention further provides kits or other 
articles of manufacture which contains a therapeutic agent of 
the present invention (e.g., antisense oligonucleotides ), tools 
for administration, and/or instructions for its use. For 
example, kits or other articles of manufacture may include 
In some embodiments, retroviral vectors are used for 
expressing an antisense oligonucleotide of interest. The 
retroviruses are a group of single-stranded RNA viruses 
characterized by an ability to convert their RNA to double-
stranded DNA in infected cells by a process of reverse-
transcription (Coffin, 1990). The resulting DNA then stably 
integrates into cellular chromosomes as a provirus and 
directs synthesis of viral proteins. The integration results in 
the retention of the viral gene sequences in the recipient cell 
and its descendants. The retroviral genome contains three 
genes, gag, pol, and env that code for capsid proteins, 
polymerase enzyme, and envelope components, respec-
tively. A sequence found upstream from the gag gene 
contains a signal for packaging of the genome into virions. 
Two long terminal repeat (LTR) sequences are present at the 
15 a container, an IDDD, a catheter and any other articles, 
devices or equipment useful in intrathecal administration 
and associated surgery. Suitable containers include, for 
example, bottles, vials, syringes (e.g., pre-filled syringes), 
ampules, cartridges, reservoirs, or lyo-jects. The container 
20 may be formed from a variety of materials such as glass or 
plastic. In some embodiments, a container is a pre-filled 
syringe. Suitable pre-filled syringes include, but are not 
limited to, borosilicate glass syringes with baked silicone 
coating, borosilicate glass syringes with sprayed silicone, or 
25 plastic resin syringes without silicone. 
Typically, the container holds formulations containing a 
therapeutic agent of the invention (e.g., antisense oligo-
nucleotides) and a label on, or associated with, the container 
that may indicate directions for reconstitution and/or use. 
5' and 3' ends of the viral genome. These contain strong 
promoter and enhancer sequences and are typically also 
required for integration in the host cell genome (Coffin, 
1990). 
30 For example, the label may indicate that the formulation is 
reconstituted to concentrations as described above. The label 
In order to construct a retroviral vector, a nucleic acid 
encoding a gene of interest is inserted into the viral genome 
in the place of certain viral sequences to produce a virus that 
is replication-defective. In some embodiments, in order to 35 
produce virions, a packaging cell line containing the gag, 
pol, and env genes but without the LTR and packaging 
components is constructed (Mann et al., 1983). When a 
recombinant plasmid containing a cDNA, together with the 
retroviral LTR and packaging sequences is introduced into 40 
this cell line (by calcium phosphate precipitation for 
example), the packaging sequence allows the RNA tran-
script of the recombinant plasmid to be packaged into viral 
particles, which are then secreted into the culture media 
(Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al., 45 
1983 ). The media containing the recombinant retroviruses is 
then collected, optionally concentrated, and used for gene 
transfer. Retroviral vectors are able to infect a broad variety 
of cell types. Suitable retroviral based vectors include, but 
are not limited to, lenitvirus based vectors including various 50 
pseuodotyped lentiviral vectors. Exemplary lentiviral vec-
tors are described in U.S. Pat. No. 5,834,256 and U.S. Pat. 
No. 5, 716,832, the teachings of which are hereby incorpo-
rated by reference. 
Other viral vectors may be employed as expression con- 55 
structs in the present invention. Vectors derived from viruses 
such as vaccinia virus (Ridgeway, 1988; Baichwal and 
Sugden, 1986; Coupar et al., 1988) adeno-associated virus 
(AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Her-
monat and Muzycska, 1984) and herpesviruses may be 60 
employed. In some embodiments, adenovirus-, or adeno-
associated virus based vectors (Levrero et al., 1991; Gomez-
Foix et al., 1992; Stratford-Perricaudet and Perricaudet, 
1991; Stratford-Perricaudet et al., 1990; Rich et al., 1993) 
are used. Various recombinant AAV vectors (e.g., AAVl, 65 
AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, or AAV8) are 
available in the art and may be used to practice the invention. 
may further indicate that the formulation is useful or 
intended for, for example, IT administration. In some 
embodiments, a container may contain a single dose of a 
stable formulation containing a therapeutic agent. In various 
embodiments, a single dose of the stable formulation is 
present in a volume of less than about 15 ml, 10 ml, 5.0 ml, 
4.0 ml, 3.5 ml, 3.0 ml, 2.5 ml, 2.0 ml, 1.5 ml, 1.0 ml, or 0.5 
ml. Alternatively, a container holding the formulation may 
be a multi-use vial, which allows for repeat administrations 
(e.g., from 2-6 administrations) of the formulation. Kits or 
other articles of manufacture may further include a second 
container comprising a suitable diluent (e.g., BWFI, saline, 
buffered saline). Upon mixing of the diluent and the formu-
lation, the final concentration of a therapeutic moiety in the 
reconstituted formulation will generally be at least 1 mg/ml 
(e.g., at least 5 mg/ml, at least 10 mg/ml, at least 25 mg/ml, 
at least 50 mg/ml, at least 75 mg/ml, at least 100 mg/ml). 
Kits or other articles of manufacture may further include 
other materials desirable from a commercial and user stand-
point, including other buffers, diluents, filters, needles, 
IDDDs, catheters, syringes, and package inserts with 
instructions for use. 
The invention will be more fully understood by reference 
to the following examples. They should not, however, be 
construed as limiting the scope of the invention. All litera-
ture citations are incorporated by reference. 
EXAMPLES 
Example 1 
Identification of Oligonucleotides that Target the 
HTR2C Exon V/Intron V Region by Oligo Walk 
As described above, the 5-HT 2 c receptor (HTR2C) plays 
an important role in the control of appetite and energy 
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balance. It has been previously demonstrated that HTR2C-
knockout mice develop hyperphagia and obesity. It was also 
reported that mice with altered HTR2C RNA editing display 
characteristics of Prader-Willi Syndrome (PWS). HTR2C 
transcripts generally undergo extensive processing in the 
region spanning the competing alternative splicing donor 
sites of exon5. HTR2C pre-mRNA forms an extensive 
base-paired structure that is subject to RNA editing and 
regulation by snoRNAs, such as psnoRNA MBII-52, which 
is missing in patients with PWS. It has been demonstrated 10 
that psnoRNA MBII-52 plays an important role in generat-
ing the non-edited HTR2C Vb isoform, which is the most 
active form of the 5-HT 2 c receptor, and it acts through 
inducing a change in alternative splicing. Kishore S. Sci-
ence, (2006), 311:230-232. 15 
This example illustrates identification of oligonucleotides 
that may substitute the loss of psnoRNA in PWS patients. 
Specifically, oligo-walking experiments were performed 
using short antisense RNA oligonucleotides complementary 
to various regions of the exon V/intron V junction of the 20 
HTR2C encompassing the psnoRNA binding region, to 
identify potential sites for altering HTR2C pre-mRNA splic-
ing (FIG. 1). Sequences of the human and mouse HTR2C 
exon V/intron V sequence are shown in Table 4 (uppercase: 
exon V, lowercase: intron V). Comparison of the exon 25 
V/intron V sequence between several different organisms are 
shown in FIG. 2 and demonstrates a high degree of homol-
ogy across different species in this region. 
TABLE 4 
HTR2C exon5/intron5 sequence 
26 
stability against exogenous nucleases and facilitate direct 
uptake by the cell. The short antisense RNA oligonucle-
otides tested include those listed in Table 5. 
TABLE 5 
Short Antisense RNA Oligonucleotides 
Oligo # Sequence ( 5' -3') SEQ ID NO, 
1 UAAUCCGAAAGUAUUGAG 1 
2 CAUAGCCGCUGCAAUUCU 4 
3 UAGCAAUCUUCAUGAUGG 10 
4 UUAGUCCGCGAAUUGAAA 11 
5 AGUAUUGAGCAUAGCCGC 5 
5-5 AGUAUUGAGCAU 
5-3 GAGCAUAGCCGC 7 
UGCAAUUCUUAUGGCCAA 8 
7 AUGCUCAAUAGGAUUACG 12 
8 AGAAAUUGCCCAAACAAU 13 
9 AAAGUUUUAUUUACCUAU 14 
In vitro RNA structure assays were performed to confirm 
binding for each of the tested antisense oligonucleotides, to 
the target region within the minigene pre-mRNA structure. 
For the study, each antisense RNA oligonucleotide was 
independently mixed with minigene pre-mRNA, hybridized 
under stringent conditions and digested with RNase A/Tl. 
Binding of the antisense RNA oligonucleotide to the mini-
gene results in a change in pre-mRNA three dimensions 
structure and its overall sensitivity to RNase cleavage. 
human HTR2c ATTATGTCTGGCCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTT SEQ ID 
exonV/intronVTATTTTCAACAGCGTCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAG N0,2 
CAATACGTAATCCTATTGAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGA 
AGATTGCTATTGTTTGGGCAATTTCTATAGgtaaataaaActttttggccataagaa 
Ttgcagcggctatgctcaatactttcggattatgtactgtgaacaacgtacagacgt 
Cgactggtaa 
mouse HTR2c ATTATGTCTGGCCTTTACCTAGATATTTGTGCCCCGTCTGGATTTCACTAGATGTGC SEQ ID 
exonV/intronVTATTTTCAACTGCGTCCATCATGCACCTCTGCGCCATATCGCTGGACCGGTATGTAG NQ,3 
CAATACGTAATCCTATTGAGCATAGCCGGTTCAATTCGCGGACTAAGGCCATCATGA 
AGATTGCCATCGTTTGGGCAATATCAATAGgtaattatacctggccatagaatTgca 
Gcggctatgctcaataccttcggattatgtactgtgaacaacctacagacgtcgact 
Ggtaa 
45 
Panel A of FIG. 3 depicts the structure of the human 
HTR2C reporter minigene (minigene) used for the oligo 
walk experiment. The minigene encompasses exon V which 
contains the alternative exon Vb region. The shaded area 
within the minigene diagram corresponds to the sequence 50 
shown in panel B. Several important elements are located 
within the exon V/intron V region, such as the snoRNA 
complementary region (framed sequence in FIG. 3B). The 
minigene was constructed as described previously (0. Stoss 
et. al., Brain Research Protocols; (4), 383; 1999). Briefly, 55 
the minigene was constructed using 3'-end sequence regions 
of exon V (approximately 100 nt in length) and the 5' end of 
intron V (approximately 97 nucleotides in length) from the 
human serotonin receptor 2C gene. The sequences were 
amplified from HEK293 genomic DNA via PCR amplifica- 60 
tion, ligated and subcloned into the pCRII vector (Invitro-
gen®) under the control of a SP6 promoter sequence. Each 
of the various short antisense RNA oligonucleotides tested 
in the oligo walk experiments are shown in FIG. 3B, along 
with their corresponding binding sites on the HTR2C pre- 65 
mRNA sequence. All of the short antisense RNA oligonucle-
otides were synthesized as 2'-0-methyl thioates, to enhance 
Following treatment, RNA was recovered and analyzed on 
a denaturing polyacrylamide gel. FIG. 4 shows exemplary 
results indicating that each of anti sense RNA oligos 1-9 bind 
to the HTR2C pre-mRNA minigene (FIG. 4). 
Example 2 
Oligo 5 and Other Oligonucleotides Promote Exon 
Vb Inclusion 
This example demonstrates that certain short antisense 
RNA oligonucleotides that bind to specific regions within 
the exon V/intron V junction of pre-mRNA sequence can 
alter splicing and promote exon Vb inclusion, resulting in 
generation of the HTR2C Vb isoform. 
For each experiment, HEK293 cells were transiently 
co-transfected, using a calcium phosphate precipitation 
method, with the HTR2C minigene plasmid, an antisense 
RNA oligo and a GFP expression vector (to visually monitor 
the rate of transfection). Specifically, HEK cells were cul-
tured in DMEM containing 10% (v/v) fetal bovine serum 
(Invitrogen). RNA oligonucleotides and plasmid DNAs 
US 9,567,585 B2 
27 
were transfected into cells with calcium phosphate. Typi-
cally, 50 ng of RNA nucleotide and 100 ng of DNA plasmid 
were transfected into lxl06 cells. Serotonin receptor 2C 
gene splicing analysis was performed as described in 
Kishore S. Science, (2006), 311:230-232. Briefly, total RNA 5 
was isolated 17-24 hours post transfection, subjected to 
RT-PCR using each antisense RNA oligonucleotide as a 
primer and the reaction product analyzed on a 2% agarose 
TBE gel (FIG. 5). The data show that antisense RNA 
oligonucleotides including oligo #5, and to a lesser extent 10 
oligo #2, and oligo #6, promoted exon Vb inclusion and led 
to generation of the HTR2C Vb splice isoform according to 
predicted band size (FIG. 5). 
As shown in FIG. 5, oligo #5 had the strongest effect on 
15 
splice site selection promoting exon Vb inclusion. Further 
experiments were performed using shortened versions of 
oligo #5, such as oligos #5-3 (GAGCAUAGCCGC), #5-5 
(AGUAUUGAGCAU), and #5-10 (GCAUAGCCGC), to 
examine if smaller regions within the foot print of oligo #5 20 
could be used to elicit the similar effect as the full length 18 
mer. Exemplary results are shown in FIGS. 5 and 6. As can 
be seen, these shortened oligonucleotides showed a smaller 
effect on exon inclusion than the full-length oligo #5. 
As shown in FIG. 3, the oligos #2, #5 and #6 all bind to 25 
intron V region that forms a stem structure with exon Vb. 
Evolutionary, this region is highly conserved, showing only 
one U38>G substitution in mouse and rat that will interfere 
with the stem, but a total of three C35>U and G129>A 
substitutions in naked mole and microbat that keep the stem 30 
structure. For example, the binding site of oligo #5 overlaps 
with about half of the psnoRNA binding site (framed 
sequence in FIG. 3) located on the complementary RNA 
strand of exon Vb. Without wishing to be bound by theory, 
35 
it is contemplated that both the psonRNA and oligo #5 target 
the same secondary structure on the HTR2C (FIG. 7). 
Example 3 
40 
Oligo #5 is Effective in the Nanomolar Range 
Oligo #5 is selected as an exemplary oligonucleotide of 
the present invention for further studies. In this example, we 
used the full length oligo #5 to determine its efficacy in cell 45 
culture and demonstrated that oligo #5 works in the nano-
molar range. 
28 
we did not observe evidence for editing, suggesting that 
oligo #5 acts directly on the RNA, without inducing an 
enzymatic modification. 
Example 4 
Oligo 5 is Successfully Delivered to Neurons of 
Hypothalamus In Vivo 
This example demonstrates that oligo 5, once injected to 
the brain, can be successfully delivered to the neurons of 
hypothalamus. 
We injected 2 µg Cy3-labeled oligo #5 stereotactically 
into the third ventricle of naive BL6 mice. Specifically, 9-12 
week old adult male naive C57BL/6 mice were stereotaxi-
cally implanted with a guide cannula to the coordinates of 
0.83 mm posterior to the bregma, 4.0 mm below the surface 
of the skull, and 0.0 mm lateral to midline. The cannula tip 
was located above the 3rd ventricle. After the surgery, the 
mice were individually housed and deprived of food with 
continuous water supply. The injection was performed 24 
hours after cannula implant. An injector with 1.0 mm 
projection (Plastics One) was inserted through the guide 
cannula and used to inject 2 ul of RNA nucleotides during 
at least 2 minutes. Food was resumed after the injection. The 
body mass and food intake were recorded at the designated 
time points. No seizures were detected in any of the mice, 
following injection of oligo #5. 
Approximately 18 hours after injection, each mouse was 
sacrificed, and the brain tissue was harvested for analysis. As 
shown in FIG. 12, 18 hours post injection, fluorescence was 
detected in the nuclei of the arcuate nucleus, which consists 
mainly of neurons, including preopiomelanocortin positive 
neurons expressing the 5-HTR2C (FIG. 11). These results 
demonstrate that oligo #5 are successfully delivered to the 
nucleus of the neurons in the hypothalamus following injec-
tion to the brain. 
Example 5 
Oligo #5 Reduces Food Intake in Mice 
As described in Examples 2 and 3, in vitro, oligo #5 
increased the abundance of the non-edited version of the 
HTR2C. Therefore, oligo #5 acts like a genetic agonist for 
the serotonin receptor 2C. In this example, we further 
demonstrated that oligo #5 causes an anorexic response in 
vivo by measuring the food intake after oligo #5 injection. 
As described above, 9-12 week old adult male naive 
C57BL/6 mice were stereotaxically implanted with a guide 
cannula to the coordinates of 0.83 mm posterior to the 
bregma, 4.0 mm below the surface of the skull, and 0.0 mm 
lateral to midline. The mice were randomly divided into 
Specifically, oligo #5 and a reporter minigene were trans-
fected into HEK293 cells as described above. Oligo #5 was 
added without transfection reagent to the cells that take up 50 
phosphor-thio RNAs. As shown in FIG. 8, the oligo starts 
showing an effect in driving the expression of the 5-HTR2C 
Vb isoform at 5 nM and the effect is strongest in the 40 nM 
range. 
55 three study groups, individually housed, deprived of food 
and given a continuous supply of water. Approximately 24 
hours post surgery, an injector with a 1.0 mm projection was 
inserted through the guide cannula and used to inject 4 µl of 
either oligo #5 or control oligo against human SMN2 at 1 
To follow the oligonucleotide in cells, we labeled either 
the 5' or 3' end with Cy3. All oligos are taken up by the cell 
and accumulate in the nucleus, as expected. As shown in 
FIG. 10, the 5' modification does not affect the effectiveness 
of oligo #5. However, in this particular experiment, the 3' 
end modification with Cy3 reduces its effectiveness (FIG. 9). 
Cy3 is attached to the last base of the oligo. 
Since psnoRNA promotes exon Vb inclusion through 
RNA editing which involves enzymatic modification, we 
determined if oligo #5 acts similarly through directly modu-
lating editing. To that end, we directly sequenced the exon 
inclusion band caused by oligo #5 and, as shown in FIG. 10, 
60 nmol (-8 µg). The third group was injected nothing (can-
nulated control). Food was resumed immediately following 
the injection. Total body mass (data not shown) and food 
intake was recorded at various time points. As shown in FIG. 
12, mice injected with oligo #5 showed a significant reduc-
65 tion in food intake for at least eight hours post the injection 
compared to both the control oligo and cannulated control 
mice. 
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We then tested if oligo #5 acts in a dose dependent 
manner. 9-12 week old adult male naive C57BL/6 mice were 
cannulated, divided up into four study groups and main-
tained as described above. Approximately 24 hours post 
surgery, the mice received either no injection, control oligo, 
30 
theory, it is contemplated that injection of oligo #5 activates 
c-fos, which triggers this "natural" cascade, thereby treating 
hyperphagia and other related symptoms in PWS and other 
diseases, disorders or conditions. 
0.1 µg of oligo #5, or 2.5 µg of oligo #5. Food was resumed 
immediately following the injection. Total body mass (data 
not shown) and food intake was recorded at various time 
points over a 2 day period. As shown in FIG. 13, oligo #5 
reduces food intake in a dose dependent manner. However, 10 
even the lower dose, 0.1 µg (20 pmol) of oligo #5, shows an 
effect in reduction of food intake by mice. 
EQUIVALENTS 
Those skilled in the art will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. The scope of the present invention is not 
intended to be limited to the above Description, but rather is 
as set forth in the appended claims. The articles "a", "an", 
and "the" as used herein in the specification and in the Taken together, injection of oligo #5 to the brain effec-
tively inhibits or reduces animal food consumption, indicat-
ing that oligo #5, and other similar oligonucleotides, can be 15 
used to treat hyperphagia in PWS patients. 
claims, unless clearly indicated to the contrary, should be 
understood to include the plural referents. Claims or descrip-
tions that include "or" between one or more members of a 
Example 6 
Exemplary Model 
As described above, our data demonstrate that small 
antisense RNA oligonucleotides 1-9 are able to bind to 
different regions within the HTR2C pre-mRNA structure, 
and some are capable of inducing changes in its three 
dimensional conformation. Our data also suggest small 
antisense oligo #5, which overlaps with approximately half 
of the snoRNA binding site located on the complementary 
RNA strand in exon Vb (FIG. 7), is able to promote exon Vb 
inclusion in vitro to produce the HTR2C Vb isoform (FIG. 
5). In vivo experiments demonstrate that injection of oligo 
#5 into the brain is directly taken up into the cell and 
dramatically reduces food intake by mice. Furthermore, 
injection of oligo #5 is able to promote an anorexic state in 
a dependent response. 
Previous studies have demonstrated that activation of the 
regulated splice site within this region of the 5-HTR2C 
pre-mRNA needs to be activated to generate the 5-HTR2C 
Vb isoform, which is the most active form of the receptor 
(Kishore et. al., Science, (311), 230; 2005). In humans, this 
is physiologically achieved through binding of psnoRNAs to 
the snoRNA-CR to alter the pre-mRNA secondary structure. 
This is supported by the findings that patients diagnosed 
with PWS, fail to produce psnoRNAs or the resulting active 
Vb isoform; leading to a state of chronic hyperphagia. This 
suggests that both the psnoRNA and oligo #5 may target the 
same secondary structure on the HTR2C pre-mRNA to 
produce the active Vb isoform (FIG. 14). 
Based on these data, and without wishing to be bound by 
any particular theory, we propose that small antisense RNA 
oligonucleotides, for example, oligo #5, can be used as a 
genetic agonist to promote generation of the active HTR2C 
Vb active isoform. As illustrated in FIG. 14, activation of the 
HTR2C receptor in POMC positive neurons quickly 
increases the transcription factor c-fos that turns on POMC 
group are considered satisfied if one, more than one, or all 
of the group members are present in, employed in, or 
otherwise relevant to a given product or process unless 
20 indicated to the contrary or otherwise evident from the 
context. The invention includes embodiments in which 
exactly one member of the group is present in, employed in, 
or otherwise relevant to a given product or process. The 
invention also includes embodiments in which more than 
25 one, or all of the group members are present in, employed in, 
or otherwise relevant to a given product or process. Further-
more, it is to be understood that the invention encompasses 
variations, combinations, and permutations in which one or 
more limitations, elements, clauses, descriptive terms, etc., 
30 from one or more of the claims is introduced into another 
claim dependent on the same base claim (or, as relevant, any 
other claim) unless otherwise indicated or unless it would be 
evident to one of ordinary skill in the art that a contradiction 
or inconsistency would arise. Where elements are presented 
35 as lists, e.g., in Markush group or similar format, it is to be 
understood that each subgroup of the elements is also 
disclosed, and any element(s) can be removed from the 
group. It should it be understood that, in general, where the 
invention, or aspects of the invention, is/are referred to as 
40 comprising particular elements, features, etc., certain 
embodiments of the invention or aspects of the invention 
consist, or consist essentially of, such elements, features, 
etc. For purposes of simplicity those embodiments have not 
in every case been specifically set forth herein. It should also 
45 be understood that any embodiment of the invention, e.g., 
any embodiment found within the prior art, can be explicitly 
excluded from the claims, regardless of whether the specific 
exclusion is recited in the specification. 
It should also be understood that, unless clearly indicated 
50 to the contrary, in any methods claimed herein that include 
more than one act, the order of the acts of the method is not 
necessarily limited to the order in which the acts of the 
method are recited, but the invention includes embodiments 
in which the order is so limited. Furthermore, where the 
55 claims recite a composition, the invention encompasses 
methods of using the composition and methods of making 
the composition. Where the claims recite a composition, it 
should be understood that the invention encompasses meth-
ods of using the composition and methods of making the 
in the arcuate nucleus. Once active, the POMC peptide is 
enzymatically processed into several small peptides such as 
alpha, beta and gamma melanocyte stimulating hormone 
(MSH). MSH peptides tum on the MC3/4R receptors in the 
paraventricular nucleus, which generate an anorexic signal. 
The same receptors inhibit the activity in the LHA (lateral 
hypothalamus), which blocks anorexic signal. As a result, 
the mice stop eating. Conversely, a subject who predomi-
nantly expresses the weakly active Vb or inactive Va iso-
form, such as in the case of a PWS patient, fails to generate 65 
sufficient c-fos activation to leave a chronic state of hyper-
phagia. Without wishing to be bound by any particular 
60 composition. 
INCORPORATION OF REFERENCES 
All publications and patent documents cited in this appli-
cation are incorporated by reference in their entirety to the 
same extent as if the contents of each individual publication 
or patent document were incorporated herein. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 28 
<210> SEQ ID NO 1 
<211> LENGTH, 36 
<212> TYPE, RNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 1 
uuggccauaa gaauugcagc 
<210> SEQ ID NO 2 
<211> LENGTH, 295 
<212> TYPE, DNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 2 
attatgtctg gee act acct 
tttcaacagc gtccatcatg 
gtaatcctat tgagcatagc 
ttgtttgggc aatttctata 
tgctcaatac tttcggatta 
<210> SEQ ID NO 3 
<211> LENGTH, 290 
<212> TYPE, DNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 3 
attatgtctg gcctttacct 
tttcaactgc gtccatcatg 
gtaatcctat tgagcatagc 
tcgtttgggc aatatcaata 
aataccttcg gattatgtac 
<210> SEQ ID NO 4 
<211> LENGTH, 18 
<212> TYPE, RNA 
sapiens 
ggcuaugcuc 
sapiens 
agatatttgt 
cacctctgcg 
cgtttcaatt 
ggtaaataaa 
tgtactgtga 
sapiens 
agatatttgt 
cacctctgcg 
cggttcaatt 
ggtaattata 
tgtgaacaac 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
cauagccgcu gcaauucu 
<210> SEQ ID NO 5 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 5 
aguauugagc auagccgc 
<210> SEQ ID NO 6 
<211> LENGTH, 12 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
aguauugagc au 
aauacu 
gccccgtctg gatttcttta gatgttttat 
ctatatcgct ggatcggtat gtagcaatac 
cgcggactaa ggccatcatg aagattgcta 
actttttggc cataagaatt gcagcggcta 
acaacgtaca gacgtcgact ggtaa 
gccccgtctg gatttcacta gatgtgctat 
ccatatcgct ggaccggtat gtagcaatac 
cgcggactaa ggccatcatg aagattgcca 
cctggccata gaattgcagc ggctatgctc 
ctacagacgt cgactggtaa 
32 
36 
60 
120 
180 
240 
295 
60 
120 
180 
240 
290 
18 
18 
12 
<210> SEQ ID NO 7 
<211> LENGTH, 12 
<212> TYPE, RNA 
33 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
gagcauagcc gc 
<210> SEQ ID NO 8 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
ugcaauucuu auggccaa 
<210> SEQ ID NO 9 
<211> LENGTH, 36 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
aguauugagc auagccgcug caauucuuau ggccaa 
<210> SEQ ID NO 10 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
uagcaaucuu caugaugg 
<210> SEQ ID NO 11 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 11 
uuaguccgcg aauugaaa 
<210> SEQ ID NO 12 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 12 
augcucaaua ggauuacg 
<210> SEQ ID NO 13 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 13 
agaaauugcc caaacaau 
<210> SEQ ID NO 14 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 14 
aaaguuuuau uuaccuau 
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-continued 
12 
18 
36 
18 
18 
18 
18 
18 
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-continued 
<210> SEQ ID NO 15 
<211> LENGTH, 36 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 15 
aguauugagc auagccgcug caauucuuau ggccaa 36 
<210> SEQ ID NO 16 
<211> LENGTH, 10 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 16 
gcauagccgc 10 
<210> SEQ ID NO 17 
<211> LENGTH, 195 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 17 
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa 60 
ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc 120 
cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca 180 
gacgucgacu gguaa 195 
<210> SEQ ID NO 18 
<211> LENGTH, 195 
<212> TYPE, RNA 
<213> ORGANISM, Macaca mulatta 
<400> SEQUENCE, 18 
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa 60 
ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc 120 
cguaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca 180 
gacgucgacu gguaa 195 
<210> SEQ ID NO 19 
<211> LENGTH, 195 
<212> TYPE, RNA 
<213> ORGANISM, Pan troglodytes 
<400> SEQUENCE, 19 
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa 60 
ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc 120 
cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca 180 
gacgucgacu gguaa 195 
<210> SEQ ID NO 20 
<211> LENGTH, 194 
<212> TYPE, RNA 
<213> ORGANISM, Canis familiar is 
<400> SEQUENCE, 20 
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa 60 
ggccaucaug aagauugcua uuguuugggc aauuucgaua gguaaauaac guucuuggcc 120 
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-continued 
auuagaauug cagcggcuau gcucaauacu uucggauuau guacugugaa caacguacag 
acgucgacug guaa 
<210> SEQ ID NO 21 
<211> LENGTH, 194 
<212> TYPE, RNA 
<213> ORGANISM, Sus scrof a 
<400> SEQUENCE, 21 
ggaucgguau guagcaauac guaauccuau 
ggccaucaug aagauugcua uuguuugggc 
aguagaauug cagcggcuau gcucaauacu 
acgucgacug guaa 
<210> SEQ ID NO 22 
<211> LENGTH, 194 
<212> TYPE, RNA 
<213> ORGANISM, Bos taurus 
<400> SEQUENCE, 22 
ggaucgguau guagcaauac guaauccuau 
ggccaucaug aagauugcua uuguuugggc 
aguagaauug cagcggcuau gcucaauacu 
acgucgacug guaa 
<210> SEQ ID NO 23 
<211> LENGTH, 190 
<212> TYPE, RNA 
<213> ORGANISM, Mus mus cul us 
<400> SEQUENCE, 23 
ggaccgguau guagcaauac 
ggccaucaug aagauugcca 
gaauugcagc ggcuaugcuc 
cgacugguaa 
<210> SEQ ID NO 24 
<211> LENGTH, 190 
<212> TYPE, RNA 
<213> ORGANISM, Rattus 
<400> SEQUENCE, 24 
ggaccgguau guagcaauac 
ggccaucaug aagauugcca 
gaauugcagc ggcuaugcuc 
cgacugguaa 
<210> SEQ ID NO 25 
<211> LENGTH, 147 
<212> TYPE, RNA 
guaauccuau 
ucguuugggc 
aauaccuucg 
rattus 
guaauccuau 
ucguuugggc 
aauaccuucg 
ugagcauagc 
aauuucuuua 
uucggauuau 
ugagcauagc 
aauuucuuua 
uucggauuau 
ugagcauagc 
aauaucaaua 
gauuauguac 
ugagcauagc 
aauaucaaua 
gauuauguac 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
cguuucaauu cacggacuaa 
gguaaugaac uuucuuggcc 
guacugugaa caacguacag 
cguuucaauu cacggacuaa 
gguaauuaac uuucuuggcc 
guacugugaa caacguacag 
cgguucaauu cgcggacuaa 
gguaauuaua ccuggccaua 
ugugaacaac cuacagacgu 
cgguucaauu cgcggacuaa 
gguaaauaua ccuggccaua 
ugugaacaac cuacagacgu 
<223> OTHER INFORMATION, Section of the Homo sapien pre-mRNA 5-HT2C 
receptor sequence 
<400> SEQUENCE, 25 
38 
180 
194 
60 
120 
180 
194 
60 
120 
180 
194 
60 
120 
180 
190 
60 
120 
180 
190 
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-continued 
uacguaaucc uauugagcau agccguuuca auucgcggac uaaggccauc auagagauug 60 
cuauuguuug ggcaauuucu auagguaaau aaaacuuuuu ggccauaaga auugcagcgg 120 
cuaugcucaa uacuuucgga uuaugua 147 
<210> SEQ ID NO 26 
<211> LENGTH, 195 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Section of the Homo sapien pre-mRNA 5-HT2C 
receptor sequence 
<400> SEQUENCE, 26 
ggaucgguau guagcaauac guaauccuau ugagcauagc cguuucaauu cgcggacuaa 60 
ggccaucaug aagauugcua uuguuugggc aauuucuaua gguaaauaaa acuuuuuggc 120 
cauaagaauu gcagcggcua ugcucaauac uuucggauua uguacuguga acaacguaca 180 
gacgucgacu gguaa 195 
<210> SEQ ID NO 27 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Sequence product for the Vb splice site 
following control treatment 
<400> SEQUENCE, 27 
gaccggtatg tagcagtgcg taatcctgtt gagcatagcc ggttc 
<210> SEQ ID NO 28 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
45 
<223> OTHER INFORMATION, Sequence product for the Vb splice junction 
following treatment with oligo 5 
<400> SEQUENCE, 28 
gaccggtatg tagcagtgcg taatcctgtt gagcatagcc ggttc 
What is claimed is: 
45 
45 
3. The antisense oligonucleotide of claim 1, wherein the 
sequence permits specific hybridization to nucleotides 10-27 
of SEQ ID NO: 1. 
4. The antisense oligonucleotide of claim 1, wherein the 
sequence permits specific hybridization to nucleotides 19-36 
of SEQ ID NO: 1. 
1. An antisense oligonucleotide of 16-50 nucleotides in 
length comprising a sequence that permits specific hybrid-
ization to a target region of a human 5'-HT2C receptor 
(HTR2C) pre-mRNA under stringent conditions, wherein: 50 
the target region comprises a nucleotide sequence 5' UUG-
GCCAUAAGAAUUGCAGCGGCUAUGCUCAAUACU 
5. The antisense oligonucleotide of claim 1, wherein the 
sequence permits specific hybridization to nucleotides 19-30 
55 of SEQ ID NO: 1. 
3' (SEQ ID NO: 1) and; 
the antisense oligonucleotide comprises a sequence at 
least 95% identical to 18 or more contiguous nucleo-
tides that appear in: 
5' AGUAUUGAGCAUAGCCGCUGCAAUUC-
UUAUGGCCAA 3' (SEQ ID NO: 15) 
and the antisense oligonucleotide comprises a ribose 
group modified with a methyl group; 
6. The antisense oligonucleotide of claim 1, wherein the 
sequence is at least 90% identical to any of 5' UGCAAUUC-
UUAUGGCCAA 3' (SEQ ID N0:8), 5' CAUAGCCGCUG-
CAAUUCU 3' (SEQ ID N0:4), 5' AGUAUUGAG-
60 CAUAGCCGC 3' (SEQ ID N0:5), or 5' 
further wherein the antisense oligonucleotide, once 
administered to a cell, modulates 5'HT2C receptor 
(HTR2C) activity. 
2. The antisense oligonucleotide of claim 1, wherein the 65 
sequence permits specific hybridization to nucleotides 1-18 
of SEQ ID NO: 1. 
GAGCAUAGCCGC 3' (SEQ ID N0:7). 
7. A pharmaceutical composition comprising the antisense 
oligonucleotide of claim 1, and a pharmaceutically accept-
able carrier. 
8. A kit comprising an antisense oligonucleotide of claim 
1; and tools for administration to the brain of a mammal. 
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9. The antisense oligonucleotide of claim 1, wherein the 
antisense oligonucleotide comprises a ribose group modified 
with a 2' 0-methyl group. 
10. The antisense oligonucleotide of claim 1, wherein the 
antisense oligonucleotide comprises one or more phospho- 5 
rothioate linkages between ribose groups. 
11. An antisense oligonucleotide, no more than 50 nucleo-
tides long, comprising a sequence that permits specific 
hybridization to a target region of a human 5'-HT2C receptor 
(HTR2C) pre-mRNA under stringent conditions, wherein: 
10 
the target region comprises a nucleotide sequence 5' 
UUGGCCAUAAGAAUUGCAGCGGCUAUGCU-
CAAUACU 3' (SEQ ID NO: 1); 
the antisense oligonucleotide is selected from the group 
consisting of 5' UGCAAUUCUUAUGGCCAA 3' 
(SEQ ID NO: 8), 5' CAUAGCCGCUGCAAUUCU 3' 15 
(SEQ ID N0:4), 5' AGUAUUGAGCAUAGCCGC 3' 
(SEQ ID N0:5), and 5' GAGCAUAGCCGC 3' (SEQ 
ID N0:7); 
the antisense oligonucleotide comprises a ribose group 
modified with a methyl group; 20 
and further wherein the antisense oligonucleotide, once 
administered to a cell, modulates 5'HT2C receptor 
(HTR2C) activity. 
42 
12. A method of modulating human 5'-HT2C receptor 
(HTR2C) activity in a cell, the method comprising deliver-
ing an antisense oligonucleotide of claim 1 to the cell. 
13. The method of claim 12, wherein the cell is a neuron. 
14. The method of claim 13, wherein the neuron is in the 
hypothalamus region of the brain. 
15. The method of claim 14, wherein the antisense oli-
gonucleotide is administered at a concentration greater than 
5 nM. 
16. A method of reducing food consumption in a subject 
comprising administering to a subject in need of treatment 
an antisense oligonucleotide of claim 1. 
17. A method of treating hyperphagia comprising admin-
istering to a subject in need of treatment an antisense 
oligonucleotide of claim 1. 
18. A method of treating obesity comprising administer-
ing to a subject in need of treatment an antisense oligo-
nucleotide of claim 1. 
19. A method of treating Prader-Willi syndrome compris-
ing administering to a subject in need of treatment an 
antisense oligonucleotide of claim 1. 
* * * * * 
